書籍詳細

1. アディポネクチン―発見・構造・発現調節・シグナル伝達

P.8 掲載の参考文献

• 1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 (2):286-289, 1996
  pubmed

• 2) Okubo K et al:Large scale cDNA sequencing for analysis of quantitative and qualitative aspects of gene expression. Nat Genet. 2 (3):173-179, 1992
  pubmed

• 3) Maeda K et al:Analysis of an expression profile of genes in the human adipose tissue. Gene 190 (2):227-235, 1997
  pubmed

• 4) Funahashi T et al:Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38 (2):202-206, 1999
  pubmed

• 5) Shimomura I et al:Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nat Med 2 (7):800-803, 1996
  pubmed

• 6) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257 (1):79-83, 1999
  pubmed

• 7) Kuriyama H et al:Molecular cloning and expression of a novel human aquaporin from adipose tissue with glycerol permeability. Biochem Biophys Res Commun 241 (1):53-58, 1997
  pubmed

• 8) Hotta K et al:Galectin-12, an Adipose-expressed Galectin-like Molecule Possessing Apoptosis-inducing Activity. J Biol Chem 276 (36):34089-34097, 2001
  pubmed

• 9) Scherer PE et al:A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270 (45):26746-26749, 1995
  pubmed

• 10) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271 (18):10697-10703, 1996

• 11) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120 (4):803-812, 1996
  pubmed

P.18 掲載の参考文献

• 1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 2) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 3) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 4) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J Biol Chem 277:37487-37491, 2002

• 5) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120:803-812, 1996
  pubmed

• 6) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 7) Tsao TS et al:Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers ctivate different signal transduction pathways. J Biol Chem 278:50810-50817, 2003
  pubmed

• 8) Hug C et al:T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101:10308-10313, 2004
  pubmed

• 9) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 10) Kobayashi Y et al:Physicochemical analysis of (Pro-Pro-Gly)n with defined molecular weight temperature dependence of molecular weight in aqueous solution. Biopolymers 9:415-425, 1970
  pubmed

• 11) Sakakibara S et al:Synthesis of(Pro-Hyp-Gly)n of defined molecular weights. Evidence for the stabilization of collagen triple helix by hydroxypyroline. Biochim Biophys Acta 303:198-202, 1973
  pubmed

• 12) Inouye K et al:Synthesis and physical properties of (hydroxyproline-proline-glycine) 10:hydroxyproline in the X-position decreases the melting temperature of the collagen triple helix. Arch Biochem Biophys 219:198-203, 1982
  pubmed

• 13) Wang Y et al:Post-translational modifications ofthe four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 281:16391-16400, 2006

• 14) Richards AA et al:Adiponectin multimerizationis dependent on conserved lysines in the collagenous domain:evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol 20:1673-1687, 2006
  pubmed

• 15) Engel J, Prockop DJ:The zipper-like folding of collagen triple helices and the effects of mutations that disrupt the zipper. Annu Rev Biophys Biophys Chem 20:137-152, 1991
  pubmed

• 16) Hoppe HJ, Reid KB:Collectins-soluble proteins containing collagenous regions and lectin domains-and their roles in innate immunity. Protein Sci 3:1143-1158, 1994
  pubmed

• 17) Ghai R et al:C1q and its growing family. Immunobiology 212:253-266, 2007
  pubmed

• 18) Weis WI et al:Physical characterization and crystallization of the carbohydrate-recognition domain of a mannose-binding protein from rat. J Biol Chem 266:20678-20686, 1991

• 19) Hoppe HJ et al:A parallel three stranded alphahelical bundle at the nucleation site of collagen triple-helix formation. FEBS Lett 344:191-195, 1994

• 20) Shapiro L, Scherer PE:The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8:335-338, 1998
  pubmed

• 21) Bogin O et al:Insight into Schmid metaphyseal chondrodysplasia from the crystal structure of the collagen X NC1 domain trimer. Structure 10:165-173, 2002
  pubmed

• 22) Kvansakul M et al:Crystal structure of the collagen alpha1 (VIII) NC1 trimer. Matrix Biol 22:145-152, 2003
  pubmed

• 23) Gaboriaud C et al:The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J Biol Chem 278:46974-46982, 2003
  pubmed

• 24) Jones EY et al:Structure of tumour necrosis factor. Nature 338:225-228, 1989

• 25) Narasimhan ML et al:Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17:171-180, 2005
  pubmed

• 26) Tischenko VM et al:Thermodynamic studies of the collagen-like region of human subcomponent C1q. A water-containing structural model. J Mol Biol 234:654-660, 1993
  pubmed

• 27) Suzuki S et al:The oligomeric structure of high molecular weight adiponectin. FEBS Lett 581:809-814, 2007
  pubmed

• 28) Shelton E et al:Ultrastructure of the human complement component, C1q (negative staining-glutamine synthetase-biologically active C1q). Proc Natl Acad Sci USA 69:65-68, 1972

• 29) Brodsky-Doyle B et al:Circular-dichroism and electron-microscopy studies of human subcomponent C1q before and after limited proteolysis by pepsin. Biochem J 159:279-286, 1976
  pubmed

• 30) Kilchherr et al:Structural model of the collagen-like region of C1q comprising the kink region and the fibre-like packing of the six triple helices. J Mol Biol 186:403-415, 1985
  pubmed

P.25 掲載の参考文献

• 1) Saito K et al:Organization of the gene for gelatin-binding protein (GBP28). Gene 229:67-73, 1999
  pubmed

• 2) Das K et al:Chromosomal localization, expression pattern, and promoter analysis of the mouse gene encoding adipocyte-specific secretory protein Acrp30. Biochem Biophys Res Commun 280:1120-1129, 2001
  pubmed

• 3) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 4) Yatagai T et al:Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52:1274-1278, 2003
  pubmed

• 5) Yamamoto Y et al:Adiponectin, an adipocyte-derived protein, predicts future insulin resistance:two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89:87-90, 2004
  pubmed

• 6) Lindsay RS et al:Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
  pubmed

• 7) Daimon M et al:Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population:the Funagata study. Diabetes Care 26:2015-2020, 2003
  pubmed

• 8) Spranger J et al:Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226-228, 2003
  pubmed

• 9) Duncan BB et al:Adiponectin and the development of type 2 diabetes:the atherosclerosis risk in communities study. Diabetes 53:2473-2478, 2004
  pubmed

• 10) Matsushita K et al:Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26:871-876, 2006
  pubmed

• 11) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 12) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 13) Adamczak M et al:Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16:72-75, 2003
  pubmed

• 14) Ouchi N et al:Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231-234, 2003
  pubmed

• 15) Nishizawa H et al:Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte derived protein. Diabetes 51:2734-2741, 2002
  pubmed

• 16) Xu A et al:Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 280:18073-18080, 2005
  pubmed

• 17) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 18) Woo JG et al:Interactions between noncontiguous haplotypes in the adiponectin gene ACDC are associated with plasma adiponectin. Diabetes 55:523-529, 2006
  pubmed

• 19) Hara K et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002
  pubmed

• 20) Vasseur F et al:Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 dia betes in French Caucasians. Hum Mol Genet 11:2607-2614, 2002

• 21) Kondo H et al:Association of adiponectin mutation with type 2 diabetes:a candidate gene for the insulin resistance syndrome. Diabetes 51:2325-2328, 2002
  pubmed

• 22) Stumvoll M et al:Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity:interaction with family history of type 2 diabetes. Diabetes 51:37-41, 2002

• 23) Menzaghi C et al:A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 51:2306-2312, 2002
  pubmed

• 24) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 25) Combs TP et al:Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists:a potential mechanism ofinsulin sensitization. Endocrinology 143:998-1007, 2002

• 26) Iwaki M et al:Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003
  pubmed

• 27) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
  pubmed

• 28) Furuhashi M et al:Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:7681, 2003

• 29) Koh KK et al:Vascular and metabolic effects of combined therapy with ramipril and simvastatinin patients with type 2 diabetes. Hypertension 45:1088-1093, 2005

• 30) Esposito K et al:Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women:a randomized trial. JAMA 289:1799-1804, 2003
  pubmed

• 31) Yang WS et al:Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819, 2001
  pubmed

• 32) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996

• 33) Flachs P et al:Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 49:394-397, 2006
  pubmed

• 34) Nagasawa A et al:Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. Horm Metab Res 34:635-639, 2002
  pubmed

• 35) Imai J et al:Cold exposure suppresses serum adiponectin levels through sympathetic nerve activation in mice. Obesity (Silver Spring) 14:1132-1141, 2006
  pubmed

• 36) Combs TP et al:Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52:268-276, 2003
  pubmed

• 37) Yamauchi T et al:Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 30:221-226, 2002
  pubmed

• 38) Chen HC et al:Obesity resistance and enhanced glucose metabolism in mice transplanted with white adipose tissue lacking acyl CoA:diacylglycerol acyltransferase 1. J Clin Invest 111:1715-1722, 2003
  pubmed

• 39) Fajas L et al:Impaired pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/-) mice. J Clin lnvest 113:1288-1295, 2004

• 40) Chevillotte E et al:Uncoupling protein-2 controls adiponectin gene expression in adipose tissue through the modulation of reactive oxygen species production. Diabetes 56:1042-1050, 2007
  pubmed

• 41) Bluher M et al:Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 3:25-38, 2002
  pubmed

• 42) Semple RK et al:Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 91:3219-3223, 2006
  pubmed

• 43) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 44) Mohlig M et al:Insulin decreases human adiponectin plasma levels. Horm Metab Res 34:655-658, 2002
  pubmed

• 45) Fasshauer M et al:Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084-1089, 2002
  pubmed

• 46) Saito K et al:Regulation of gelatin-binding protein 28 (GBP28) gene expression by C/EBP. Biol Pharm Bull 22:1158-1162, 1999

• 47) Park BH et al:Phosphorylation of C/EBPbeta at a consensus extracellular signal-regulated kinase/glycogen synthase kinase 3 site is required for the induction of adiponectin gene expression during the differentiation of mouse fibroblasts into adipocytes. Mol Cell Biol 24:8671-8680, 2004

• 48) Kita A et al:Identification of the promoter region required for human adiponectin gene transcription:Association with CCAAT/enhancer binding protein-beta and tumor necrosis factor-alpha. Biochem Biophys Res Commun 331:484-490, 2005
  pubmed

• 49) Park SK et al:CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes 53:2757-2766, 2004
  pubmed

• 50) Qiao L et al:C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 54:1744-1754, 2005

• 51) Seo JB et al:Adipocyte determination-and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J Biol Chem 279:22108-22117, 2004
  pubmed

• 52) Qiao L, Shao J:SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer binding protein alpha transcriptional complex. J Biol Chem 281:39915-39924, 2006
  pubmed

• 53) Qiang L et al:Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol 27:4698-4707, 2007
  pubmed

• 54) Kim HB et al:NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. Diabetes 55:1342-1352, 2006
  pubmed

• 55) Chandrasekar B et al:Interleukin-18 suppresses adiponectin expression in 3T3-L1 adipocytes via a novel signal transduction pathway involving ERK1/2-dependent NFATc4 phosphorylation. J Biol Chem 283:4200-4209, 2008

• 56) Ikeda K et al:Transcription factor activating enhancer-binding protein-2beta. A negative regulator of adiponectin gene expression. J Biol Chem 281:31245-31253, 2006
  pubmed

• 57) Barth N et al:Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter:role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia 45:1425-1433, 2002

P.35 掲載の参考文献

• 1) Shimomura I et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999
  pubmed

• 2) Kadowaki T, Yamauchi T:Adiponectin and adiponectin receptors. Endocr Rev 26:439-451, 2005
  pubmed

• 3) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 4) Mori Y et al:Genome-wide search for type 2 diabetes in Japanese affected sibpairs confirms susceptibility genes on 3q, 15q and 20q and identifies two new candidate loci on 7p and 11p. Diabetes 51:1247-1255, 2002
  pubmed

• 5) Vionnet N et al:Genomewide search for type 2 diabetes-susceptibility genes in French whites:evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 67:1470-1480, 2000
  pubmed

• 6) Kissebah AH et al:Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 97:14478-14483, 2000
  pubmed

• 7) Kadowaki T et al:Molecular mechanism of insulin resistance and obesity. Exp Biol Med (Maywood) 228:1111-1117, 2003
  pubmed

• 8) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 9) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 10) Hara K et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese Population. Diabetes 51:536-540, 2002
  pubmed

• 11) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 12) Hara K et al:Absence of an association between the polymorphisms of the genes encoding adiponectin receptors and type 2 diabetes. Diabetologia 48:1307-1314, 2005
  pubmed

• 13)遺伝医学関連学会:遺伝学的検査に関するガイドライン

P.44 掲載の参考文献

• 1) Kadowaki T et al:Adiponectin and adiponect in receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006

• 2) Scherer PE et al:A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
  pubmed

• 3) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996

• 4) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 5) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120:803-812, 1996
  pubmed

• 6) Yokota T et al:Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732, 2000
  pubmed

• 7) Shapiro L, Scherer PE:The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8:335-338, 1998
  pubmed

• 8) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 9) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 10) Tsao TS et al:Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278:50810-50817, 2003
  pubmed

• 11) Suzuki S et al:The oligomeric structure of high molecular weight adiponectin. FEBS Lett 581:809-814, 2007
  pubmed

• 12) Wang Y et al:Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 281:16391-16400, 2006
  pubmed

• 13) Richards AA et al:Adiponectin multimerization is dependent on conserved lysines in the collagenous domain:evidence for regulation of multimerization by alterations in posttranslational modifications. Mol Endocrinol 20:1673-1687, 2006
  pubmed

• 14) Hada Y et al:Selective purification and characterization of adiponectin multimer species from human plasma. Biochem Biophys Res Commun 356:487-493, 2007
  pubmed

• 15) Kadowaki T, Yamauchi T:Adiponectin and adiponectin receptors. Endocr Rev 26:439-451, 2005
  pubmed

• 16) Wang ZV et al:Adiponectin, cardiovascular function, and hypertension. Hypertension 51:8-14, 2008
  pubmed

• 17) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 18) Berg AH et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
  pubmed

• 19) Pajvani UB et al:Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

• 20) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 21) Fruebis J et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001
  pubmed

• 22) Tomas E et al:Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain:acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309-16313, 2002
  pubmed

• 23) Waki H et al:Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146:790-796, 2005
  pubmed

• 24) Wang Y et al:Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280:18341-18347, 2005

• 25) Tsao TS et al:Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359-29362, 2002
  pubmed

• 26) Ebinuma H et al:Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid. Clin Chem 53:1541-1544, 2007
  pubmed

• 27) Kubota N et al :Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55-68, 2007
  pubmed

• 28) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 29) Ebinuma H et al:A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 372:47-53, 2006
  pubmed

• 30) Nakano Y et al:A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 47:1572-1582, 2006
  pubmed

• 31) Lara-Castro C et al:Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55:249-259, 2006
  pubmed

• 32) Fisher FF et al:Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia 48:1084-1087, 2005

• 33) Hara K et al:Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357-1362, 2006
  pubmed

• 34) Basu R et al:Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes:differential regulation from nondiabetic subjects. Diabetes 56:2174-2177, 2007
  pubmed

• 35) Kobayashi H et al:Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004
  pubmed

• 36) Bobbert T et al:Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54:2712-2719, 2005
  pubmed

• 37) Salani B et al:High-molecular weight adiponectin isoforms increase after biliopancreatic diversion in obese subjects. Obesity (SilverSpring) 14:1511-1514, 2006

• 38) Swarbrick MM et al:Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 49:2552-2558, 2006
  pubmed

• 39) Bodles AM et al:Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes. Am J Physiol Endocrinol Metab 291:E1100-1105, 2006
  pubmed

• 40) Fasshauer M et al:Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084-1089, 2002
  pubmed

• 41) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
  pubmed

• 42) Iwaki M et al:Induction of adiponectin, a fat-derived antidiabetic andd antiatherogellic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003

• 43) Wang ZV et al:Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol 27:3716-3731, 2007
  pubmed

• 44) Qiang L et al:Adiponectin secretion is regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L alpha. Mol Cell Biol 27:4698-4707, 2007
  pubmed

• 45) Qiao L, Shao J:SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 281:39915-39924, 2006
  pubmed

P.50 掲載の参考文献

• 1) Matsuzawa Y et al:Molecular mechanism of metabolic syndrome X:contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146-154, 1999
  pubmed

• 2) 広瀬寛ほか:インスリン抵抗性とサイトカイン. Diabetes Frontier 12:590-596, 2001
  Medical*Online

• 3) 広瀬寛ほか:メタボリックシンドロームの診断・治療に役立つ血中マーカー:高分子量アディポネクチン. 内分泌・糖尿病科 24:459-466, 2007

• 4) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 5) Hotta K et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 6) Kobayashi H et al:Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004
  pubmed

• 7) Pajvani UB et al:Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

• 8) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes:Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 9) Wang Y et al:Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280:18341-18347, 2005

• 10) Yamamoto Y et al:Correlation of adipocyte-derived protein, adiponectin with insulin resistance index and serum HDL-cholesterol, independent of body mass index in the Japanese population. Clin Sci 103:137-142, 2002
  pubmed

• 11) Nakano Y et al:A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 47:1572-1582, 2006
  pubmed

• 12) Hirose H et al:Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314-317, 2002
  pubmed

• 13) Yamamoto Y et al:Adiponectin, an adipocyte-derived protein, predicts future insulin resistance:two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89:87-90, 2004
  pubmed

• 14) Seino Y et al:High molecular weight (HMW) multimer form of adiponectin as a useful marker to evaluate insulin resistance and metabolic syndrome in Japanese men. Metabolism 56 (11):1493-1499, 2007
  pubmed

• 15) Daimon M et al:Decreased serum levels ofadiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population:the Funagata study. Diabetes Care 26:2015-2020, 2003

• 16) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 17) Kawai T et al:Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 48:1102-1107, 1999
  pubmed

• 18) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
  pubmed

• 19) Yang WS et al:Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380, 2002
  pubmed

• 20) Vionnet N et al:Genomewide search for type 2 diabetes-susceptibility genes in French whites:evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabeteslocus on chromosome 1q21-q24. Am J Hum Genet 67:1470-1480, 2000
  pubmed

• 21) Kissebah AH et al:Quantitative trait loci onchromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 97:14478-14483, 2000
  pubmed

• 22) Hara K et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002
  pubmed

• 23) Kondo H et al:Association of adiponectin mutation with type 2 diabetes:a candidate gene for the insulin resistance syndrome. Diabetes 51:2325-2328, 2002
  pubmed

• 24) Yamamoto Y et al:PPARgamma2 gene Pro12Ala polymorphism may influence serum level of an adipocyte-derived protein, adiponectin, in the Japanese population. Metabolism 51:1407-1409, 2002
  pubmed

P.57 掲載の参考文献

• 1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 2) 船橋 徹:アディポネクチン-その発見から機能解析への道-. 肥満研究 9:224-234, 2003
  Medical*Online

• 3) Sivan E et al:Adiponectin in human cord blood:Relation to fetal birth weight and gender. J Clin Endocrinol Metab 88:5656-5660, 2003

• 4) Lindsay RS et al:Adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care 26:2244-2249, 2003
  pubmed

• 5) Reitman ML et al:Leptin and its role in pregnancy and fetal development:an overview. Biochem Soc Trans 29:68-72, 2001
  pubmed

• 6) Kajantie E et al:Cord plasma adiponectin:A 20-fold rise between 24 weeks gestation and term. J Clin Endocrinol Metab 89:4031-4036, 2004
  pubmed

• 7) Viengchareun S et al:Brown adipocytes are novel sites of expression and regulation of adiponectin and resistin. FEBS Lett 532:345-350, 2002
  pubmed

• 8) Fasshauer M et al:Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084-1089, 2002
  pubmed

• 9) Corbetta S et al:Adiponectin expression in human fetal tissue during mid-and late gestation. J Clin Endocrinol Metab 90:2397-2402, 2005
  pubmed

• 10) Stefan N et al:Plasma adiponectin concentrations in children:Relationships with obesity and insulinemia. J Clin Endocrinol Metab 87:4652-4656, 2002
  pubmed

• 11) 原光彦ほか:学童における血中アディポネクチンの性差年齢差と各種身体計測指標・血圧・血清 脂質・肥満との関係について. 肥満研究 10:157-162, 2004
  Medical*Online

• 12) Ong KK et al:Sex-discordant associations with adiponectin levels and lipid profiles in children. Diabetes 55:1337-1341, 2006
  pubmed

• 13) Caprio S:Relationship between abdominal visceral fat and metabolic risk factors in obese adolescents. Am J Hum Biol 11:259-266, 1999
  pubmed

• 14) Nishizawa H et al:Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734-2741, 2002
  pubmed

• 15) Bottner A et al:Gender difference of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab 89:4053-4061, 2004

• 16) Woo JG et al:Adolescent sex differences in adiponectin are conditional on pubertal development and adiposity. Obesity Research 13:2095-2101, 2005
  pubmed

• 17) Ryo M et al:Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 18) Aso Y et al:Comparison od serum high-molecular weight adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMV adiponectin. Diabetes 55:1954-1960, 2006

• 19) Araki S et al:High molecular weight, rather than total, adiponectin levels better reflect metabolic abnormalities associated with childhood obesity. J Clin Endocrinol Metab 91:5113-5116, 2006
  pubmed

P.66 掲載の参考文献

• 1) 杉浦甫ほか:肥満についての, 新しい細胞生物学的分類の提唱. 肥満研究 8 (2):17-22, 2002

• 2) Stahl A et al:Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev Cell 2:477-488, 2002
  pubmed

• 3) Kubota N et al:PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609, 1999
  pubmed

• 4) Okuno A et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
  pubmed

• 5) Kadowaki T, Yamauchi T:Adiponectin and adiponectin receptors. Endocr Rev 26:439-451, 2005
  pubmed

• 6) Bogan JS et al :Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol 146:609-620, 1999
  pubmed

• 7) Gustafson B et al:Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 308:933-939, 2003

• 8) Hiuge A et al:Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27:635-641, 2007
  pubmed

• 9) Qiao L et al:C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes 54:1744-1754, 2005

• 10) Kita A et al:Identification of the promoter region required for human adiponectin gene transcription:Association with CCAAT/enhancer binding protein-beta and tumor necrosis factor-alpha. Biochem Biophys Res Commun 331:484-490, 2005
  pubmed

• 11) Barth N et al:Identification of regulatory elements in the human adipose most abundant gene transcript-1 (apM-1) promoter:role of SP1/SP3 and TNF-alpha as regulatory pathways. Diabetologia 45:1425-1433, 2002, Erratum in:Diabetologia 47:153, 2004

• 12) Iwaki M et al:Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003
  pubmed

• 13) Seo JB et al:Adipocyte determination-and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J Biol Chem 279:22108-22117, 2004
  pubmed

• 14) Qiao L, Shao J:SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex. J Biol Chem 281:39915-39924, 2006
  pubmed

• 15) Natarajan R et al:Hypoxia Inducible Factor-1 Upregulates Adiponectin in Diabetic Mouse Hearts And Attenuates Post-Ischemic Injury. J Cardiovasc Pharmacol 51:178-187, 2008
  pubmed

• 16) Ikeda K et al:Transcription factor activating enhancer-binding protein-2beta. A negative regulator of adiponectin gene expression. J Biol Chem 281:31245-31253, 2006
  pubmed

• 17) Kim HB et al:NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. Diabetes 55:1342-1352, 2006
  pubmed

• 18) Deng J et al:Protein inhibitor of activated STAT3 inhibits adipogenic gene expression. Biochem Biophys Res Commun 339:923-931, 2006
  pubmed

• 19) Tsao TS et al:Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359-29362, 2002
  pubmed

• 20) Nishimura S et al:In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest 118:710-721, 2008
  pubmed

• 21) Ito A et al:Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. J Biol Chem 282:25445-25452, 2007
  pubmed

• 22) Wu JJ et al :Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab 4:61-73, 2006
  pubmed

• 23) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13 (3):332-339, 2007
  pubmed

• 24) Bauche IB et al:Overexpression of adiponectin targeted to adipose tissue in transgenic mice:impaired adipocyte differentiation. Endocrinology 148:1539-1549, 2007
  pubmed

P.74 掲載の参考文献

• 1) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 2) Matsuzawa Y et al:Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 3) Trujillo ME, Scherer PE:Adipose tissue-derived factors:impact on health and disease. Endocr Rev 27:762-778, 2006
  pubmed

• 4) Grundy SM:Drug therapy of the metabolic syndrome:minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5:295-309, 2006
  pubmed

• 5) Kershaw EE, Flier JS:Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556, 2004

• 6) Semple RK et al:PPARγ and human metabolic disease. J Clin Invest 116:581-589, 2006

• 7) Montague CT, O'Rahilly S:The perils of portliness. Cause and consequences of visceral adiposity. Diabetes 49:883-888, 2000
  pubmed

• 8) Wajchenberg BL:Subcutaneous and visceral adipose tissue:Their relation to the metabolic syndrome. Endocr Rev 21:697-738, 2000

• 9) Degawa-Yamauchi M et al:Regulation of adiponectin expression in human adipocytes:Effects of adiposity, glucocorticoids, and tumor necrosis factor alfa. Obes Res 13:662-669, 2005

• 10) Masuzaki H et al:Atransgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170, 2001

• 11) Kershaw EE et al:Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54:1023-1031, 2005
  pubmed

• 12) Fasshauer M et al:Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301:1045-1050, 2003
  pubmed

• 13) Hoo RL et al:Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler Thromb Vasc Biol 27:2777-2782, 2007
  pubmed

• 14) Masuzaki H, Flier JS:Tissue-specific glucocorticoid reactivating enzyme, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD 1). -A promising drug target for the treatment of the Metabolic Syndrome-. Curr Drug Targets Immmune Endocr Metabol Disord 3:255-262, 2003

• 15) Masuzaki H et al:Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112:83-90, 2003
  pubmed

• 16) Yeager MP et al:Glucocorticoid regulation of the inflammatory response to injury. Acta Anaesthesiol Scand 48:799-813, 2004
  pubmed

• 17) Ishii T et al:Augmentation of 11β-hydroxysteroid dehydrogenase type 1 in LPS-activated J774.1 macrophages-Role of 11β-HSD1 in proinflammatory properties in macrophages-. FEBS Lett 581:349-354, 2007

• 18) Nakano S et al:Bezafibrate regulates the expression and enzyme activity of 11β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 292 :E1213-E1222, 2007

• 19) Arai N et al:Ceramide and AMP-activated protein kinase are two novel reglators of 11 β-hydroxysteroid dehydrogenase type 1 expression and activity in cultured preadipocytes. Endocrinology 148:5268-5277, 2007

• 20) Nishizawa H et al:Androgen decreases plasma adiponectin, an insulin-sensitizing adipocyte derived protein. Diabetes 51:2734-2741, 2002

P.85 掲載の参考文献

• 1) Hardie DG et al:The AMP-activated/SNF1 protein kinase subfamily:metabolic sensors of the eukaryotic cell? Annu Rev Biochem 67:821-855, 1998
  pubmed

• 2) Winder WW:Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 91:1017-1028, 2001
  pubmed

• 3) Dolinsky VW, Dyck JR:Role of AMP-activated protein kinase in healthy and diseased hearts. Am J Physiol Heart Circ Physiol 291:H2557-2569, 2006
  pubmed

• 4) Minokoshi Y et al:Leptin stimulates fatty acid oxidation by activating of AMP-activated protein kinase. Nature 415:339-343, 2002
  pubmed

• 5) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 6) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 7) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponect in binding and metabolic actions. Nat Med 13:332-339, 2007

• 8) Banerjee RR et al:Regulation of fasted blood glucose by resistin. Science 303:1195-1198, 2004
  pubmed

• 9) Steinberg GR et al:Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4:465-474, 2006
  pubmed

• 10) Minokoshi Y et al :AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569-574, 2004
  pubmed

• 11) Kubota N et al:Adiponectin stimulates AMP activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55-68, 2007
  pubmed

• 12) Kahn BB et al:AMP-activated protein kinase:ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25, 2005

• 13) Suzuki A et al :Leptin stimulates fatty acid oxidation and PPARα gene expression in mouse C2C12 myoblasts by changing the suubcellular localization of the α2 form of AMP-activated protein kinase. Mol Cell Biol 27:4317-4327, 2007

• 14) Alessi DR et al:LKB1-dependent signaling pathways. Annu Rev Biochem 75:137-163, 2006
  pubmed

• 15) Hong SP et al:Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci USA 100:8839-8843, 2003
  pubmed

• 16) Hawley SA et al:Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28, 2003
  pubmed

• 17) Hardie DG et al:AMPK:a key sensor of fuel and energy status in skeletal muscle. Physiology 21:48-60, 2006
  pubmed

• 18) Shaw RJ et al:The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646, 2005
  pubmed

• 19) Hamilton SR et al:AMP-activated protein kinase kinase:detection with recombinant AMPK alphal subunit. Biochem Biophys Res Commun 293:892-898, 2002

• 20) Hawley SA et al:Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2:9-19, 2005
  pubmed

• 21) Woods A et al:CaL2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab 2:21-33, 2005

• 22) Hurley RL et al:The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem 280:29060-29066, 2005
  pubmed

• 23) Momcilovic M et al:Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 281:25336-25343, 2006
  pubmed

• 24) Shibuya H et al:TAB 1:an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272:1179-1182, 1996

• 25) Mu J et al:A role for AMP-activated protei nkinase in contraction-and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7:1085-1094, 2001

• 26) Fujii N et al:AMP-activated protein kinase α2 activity is not essential for contraction-and hyperosmolarity-induced glucose transport in skeletal muscle. J Biol Chem 280:39033-39041, 2005

• 27) Abu-Elheiga L et al:Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291:2613-2616, 2001
  pubmed

• 28) Jager S et al:AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1 α. Proc Natl Acad Sci USA 104:12017-12022, 2007

• 29) Koves TR et al:Mitochondrial overload and incomplete Fatty Acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7:45-56, 2008
  pubmed

• 30) Koo SH et al:The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437:1109-1111, 2005
  pubmed

• 31) Narasimhan ML et al:Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17:171-180, 2005
  pubmed

• 32) Hug C et al:T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101:10308-10313, 2004
  pubmed

• 33) Mao X et al:APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8:516-523, 2006
  pubmed

• 34) Wang C et al:Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 282:7991-7996, 2007
  pubmed

• 35) Shibata R et al:Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384-1389, 2004
  pubmed

• 36) Shibata R et al:Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096-1103, 2005
  pubmed

• 37) Xue B, Kahn BB:AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 574:73-83, 2006
  pubmed

• 38) Wolfgang MJ, Lane MD:T he role of hypothalamic malonyl-CoA in energy homeostasis. J Biol Chem 281:37265-37269, 2006

• 39) He W et al:Molecular disruption of hypothalamic nutrient sensing induces obesity. Nat Neurosci 9:227-233, 2006
  pubmed

• 40) Gao S et al:Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc Natl Acad Sci USA 104:17358-17363, 2007
  pubmed

• 41) Cota D et al:Hypothalamic mTOR signaling regulates food intake. Science 312:927-930, 2006
  pubmed

P.93 掲載の参考文献

• 1) Issemann I, Green S:Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645-650, 1990
  pubmed

• 2) Michalik L et al:International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58:726-741, 2006
  pubmed

• 3) Lee CH et al:Minireview:lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144:2201-2207, 2003
  pubmed

• 4) Lin J et al:Metabolic control through PGC-1 family of transcription coactivators. Cell Metab 1:361-370, 2005

• 5) Diradourian C et al:Phosphorylation of PPARs:from molecular characterization to physiological relevance. Biochimie 87:33-38, 2005
  pubmed

• 6) Burns KA, Vanden Heuvel JP:Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771:952-960, 2007
  pubmed

• 7) Shalev A et al:The peroxisome proliferator-activated receptor alpha is a phosphoprotein:regulation by insulin. Endocrinology 137:4499-4502, 1996
  pubmed

• 8) Juge-Aubry CE et al:Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor α by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem 274:10505-10510, 1999

• 9) Barger PM et al:p38 mitogen-activated protein kinase activates peroxisome proliferators-activated receptor alpha. a potential role in the cardiac metabolic stress response. J Biol Chem 276:44495-44501, 2001

• 10) Yoon MJ et al:Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 55:2562-2570, 2006
  pubmed

• 11) Lazennec G et al:Activation of peroxisome proliferator-activated receptors(PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 14:1962-1975, 2000
  pubmed

• 12) Blanquart C et al:The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. Mol Endocrinol 18:1906-1918, 2004
  pubmed

• 13) Gray JP et al:Regulation of peroxisome proliferator-activated receptor alpha by protein kinase C. Biochemistry 44:10313-10321, 2005
  pubmed

• 14) Hotta K et al:Plasma concentration of a novel adipose-specifc protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000

• 15) Hotta K et al:Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001
  pubmed

• 16) Fruebis J et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001
  pubmed

• 17) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2 767-2770, 2002

• 18) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 19) Berg AH et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
  pubmed

• 20) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 21) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 22) Carling D:AMP-activated protein kinase:balancing the scales. Biochimie 87:87-91, 2005
  pubmed

• 23) Schimmack G et al:AMP-activated protein kinase:role in metabolism and therapeutic implications. Diabetes Obes Metab 8:591-602 , 2006
  pubmed

• 24) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 25) You M et al:The role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42:568-577, 2005
  pubmed

• 26) Fujita K et al:Adiponectin protects against angiotensin II-induced cardiac fibrosis throughactivation of PPARalpha. Arterioscler Thromb Vasc Biol 28:863-870, 2008.
  pubmed

• 27) Barger PM et al:Deactivation of peroxisome proliferator-activated receptor α during cardiac hypertrophic growth. J Clin Invest 105:1723-1730 , 2000

• 28) Suzuki A et al:Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the α2 form of AMP-activated protein kinase. Mol Cell Biol 27:4317-4327, 2007

2. アディポネクチンの多彩な作用とメカニズム

P.102 掲載の参考文献

• 1) Lazar MA:The humoral side of insulin resistance. Nat Med 12:43-44, 2006
  pubmed

• 2) Kershaw EE, Flier JS:Adipose Tissue as an Endocrine Organ. J Clin Endocrinol Metab 89:2548-2556, 2004

• 3) Pittas AG et al:Adipocytokines and Insulin Resistance. J Clin Endocrinol Metab 89:447-452, 2004
  pubmed

• 4) Weisberg SP et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:179-1808, 2003

• 5) Xu A et al:The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112:91-100, 2003
  pubmed

• 6) Kanda H et al:MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494-1505, 2006

• 7) Suzuki R et al:Expression of DGAT2 in white adipose tissue is regulated by central leptin action. J Biol Chem 280:3331-3337, 2005
  pubmed

• 8) Weisberg SP et al:CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115-124, 2006
  pubmed

• 9) Nakano Y et al:Isolation and Characterization of GBP28, a Novel Gelatin-Binding Protein Purified from Human Plasma. J Biochem (Tokyo) 120:803-812, 1996
  pubmed

• 10) Maeda K et al:cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1 (AdiPose Most Abundant Gene Transcript 1). Biochem Biophys Res Commun 221:268-289, 1996

• 11) Scherer PE et al:A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes. J Biol Chem 270:26746-26749, 1995
  pubmed

• 12) Hu E et al:AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity. J Biol Chem 271:10697-10703, 1996

• 13) Arita Y et al:Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 14) Hotta K et al:Circulating Concentrations of the Adipocyte Protein Adiponectin Are Decreased in Parallel with Reduced Insulin Sensitivity During the Progression to Type 2 Diabetes in Rhesus Monkeys. Diabetes 50:1126-1133, 2001
  pubmed

• 15) Hotta K et al:Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 16) Kubota N et al:Adiponectin Stimulates AMP-Activated Protein Kinase in the Hypothalamus and Increases Food Intake. Cell Metab 6:55-68, 2007
  pubmed

• 17) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 18) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 19) Berg AH et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
  pubmed

• 20) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 21) McGarry JD, Brown NF:The Mitochondrial Carnitine Palmitoyltransferase System. From Concept to Molecular Analysis. Eur J Biochem 244:1-14, 1 997

• 22) Winder WW, Hardie DG:AMP-activated protein kinase, a metabolic master switch:possible roles in type 2 diabetes. Am J Physiol 277:E1-10, 1999
  pubmed

• 23) Long YC, Zierath JR:AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116:1776-1783, 2006
  pubmed

• 24) Yamauchi T et al:Globular Adiponectin Protected ob/ob Mice from Diabetes and ApoE-deficient Mice from Atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 25) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

• 26) Koo SH et al:T he CREB coactivator TORC2 is akey regulator of fasting glucose metabolism. Nature 437:1109-1111, 2005

• 27) Combs TP et al:A Transgenic Mouse with a Deletion in the Collagenous Domain of Adiponectin Displays Elevated Circulating Adiponectin and Improved Insulin Sensitivity. Endocrinology 145:367-383, 2004
  pubmed

• 28) Kubota N et al:D isruption of Adiponectin Causes Insulin Resistance and Neointimal Formation. J Biol Chem 277:25863-25866, 2002,

• 29) Maeda N et al:Diet-induced insulin resistancein mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002

• 30) Ma K et al:Increased beta-Oxidation but No Insulin Resistance or Glucose Intolerance in Mice Lacking Adiponectin. J Biol Chem 277:34658-34661, 2002
  pubmed

• 31) Nawrocki AR et al:Mice Lacking Adiponectin Show Decreased Hepatic Insulin Sensitivity and Reduced Responsiveness to Peroxisome Proliferator-activated Receptor γ Agonists. J Biol Chem 281:2654-2660, 2006

• 32) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 33) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

• 34) Shimano H et al:Isoform 1c of Sterol Regulatory Element Binding Protein Is Less Active Than Isoform 1a in Livers of Transgenic Mice and in Cultured Cells. J Clin Invest 99:846-854, 1997
  pubmed

• 35) Herberg L, Coleman DL:Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism 26:59-99, 1977
  pubmed

• 36) Bray GA, York DA:Hypothalamic and genetic obesity in experimental animals:an autonomic and endocrine hypothesis. Physiol Rev 59:719-809, 1979
  pubmed

• 37) Yahagi N et al:Absence of Sterol Regulatory Element-binding Protein-1 (SREBP-1) Ameliorates Fatty Livers but Not Obesity or Insulin Resistance in Lepob/Lepob Mice. J Biol Chem 277:19353-19357, 2002

• 38) Zhou G et al:Role of AMP-activated protei nkinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001

P.108 掲載の参考文献

• 1) Shulman GI:Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000
  pubmed

• 2) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 3) Yamauchi T et al:Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013, 2001
  pubmed

• 4) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 5) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 6) Zhou G et al:Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
  pubmed

• 7) Wu X et al:Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52:1355-1363, 2003
  pubmed

• 8) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 9) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

• 10) Civitarese AE et al:Role of adiponectin in human skeletal muscle bioenergetics. Cell Metab 4:75-87, 2006
  pubmed

P.114 掲載の参考文献

• 1) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 2) Scherer PE:Adipose tissue:from lipid storage compartment to endocrine organ. Diabetes 55:1537-1545, 2006
  pubmed

• 3) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 4) Berg AH et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
  pubmed

• 5) Fruebis J et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001
  pubmed

• 6) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 7) Nawrocki AR et al:Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654-2660, 2006
  pubmed

• 8) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 9) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 10) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 11) Spranger J et al:Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55:141-147, 2006

• 12) Kubota N et al:Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55-68, 2007
  pubmed

• 13) Kos K et al:Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab 92:1129-1136, 2007
  pubmed

• 14) Qi Y et al:Adiponectin acts in the brain to decrease body weight. Nat Med 10:524-529, 2004
  pubmed

• 15) Kusminski CM et al:Adiponectin complexes in human cerebrospinal fluid:distinct complex distribution from serum. Diabetologia 50:634-642, 2007
  pubmed

• 16) Ebinuma H et al:Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid. Clin Chem 53:1541-1544, 2007
  pubmed

• 17) Andersson U et al:AMP-activated proteinkinase plays a role in the control of food intake. J Biol Chem 279:12005-12008, 2004

• 18) Hardie DG:The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 117:5479-5487, 2004
  pubmed

• 19) Carling D:AMP-activated protein kinase:balancing the scales. Biochimie 87:87-91, 2005
  pubmed

• 20) Xue B, Kahn BB:AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 574:73-83, 2006
  pubmed

• 21) Minokoshi Y et al:AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428:569-574, 2004
  pubmed

• 22) Kadowaki T et al:The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Lett 582 (1):74-80, 2008
  pubmed

• 23) Karpichev IV et al:M ultiple regulatory roles of a novel Saccharomyces cerevisiae protein, encoded by YOL002c, in lipid and phosphate metabolism. J Biol Chem 277:19609-19617, 2002

P.120 掲載の参考文献

• 1) Scherer PE et al:A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
  pubmed

• 2) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996

• 3) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 4) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120:803-812, 1996
  pubmed

• 5) Hara K et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002
  pubmed

• 6) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 7) Kharroubi I et al:Expression of adiponectin receptors in pancreatic β cells. Biochem Biophys Res Commun 312:1118-1122, 2003

• 8) Rakatzi I et al:Adiponectin counteracts cytokine-and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249-258, 2004
  pubmed

• 9) Winzell MS et al:Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 321:154-160, 2004
  pubmed

• 10) Okamoto M et al:Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 51:827-835, 2008

• 11) Ohara-Imaizumi M et al:TIRF imaging of docking and fusion of single insulin granule motion in primary rat pancreatic beta-cells:different behaviour of granule motion between normal and Goto-Kakizaki diabetic rat beta-cells. Biochem J 381:13-18, 2004
  pubmed

• 12) Staiger K et al:Adiponectin is functionally active in human islets but dose not affect insulin secretory function or β-cell lipoapoptosis. J Clin Endocrinol Metab 90:6707-6713, 2005

• 13) Zawalich WS et al:Insulin secretion, inositol phosphate levels, and phospholipase C isozymes in rodent pancreatic islets. Metabolism 49:1156-1163, 2000
  pubmed

• 14) Pajvani UB et al:Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

• 15) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 16) Tsuchida A et al:Peroxisome proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54:3358-3370, 2005
  pubmed

• 17) Narasimhan ML et al:0smotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17 (2):171-180, 2005
  pubmed

P.128 掲載の参考文献

• 1) Cnop M et al:Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins:evidence for independent roles of age and sex. Diabetologia 46:459-469, 2003
  pubmed

• 2) Ryo M et al:Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 3) Zoccali C et al:Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141, 2002
  pubmed

• 4) Yokoyama S:Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 26:20-27, 2006
  pubmed

• 5) Matsuura F et al:Adiponectin accelerates reverse cholesterol transport by increasing highdensity lipoprotein assembly in the liver. Biochem Biophys Res Commun 358:1091-1095, 2007

• 6) Neumeier M et al:High molecular weight adiponectin reduces apolipoprotein B and E release in human hepatocytes. Biochem Biophys Res Commun 352:543-548, 2007

• 7) Duez H et al:Regulation of human apoA-I bygemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 25:585-591, 2005
  pubmed

• 8) Chinetti G et al:PPAR-alpha and PPAR-gammaactivators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001
  pubmed

• 9) Verges B et al:Adiponectin is an important determinant of apoA-I catabolism. Arterioscler Thromb Vasc Biol 26:1364-1369, 2006
  pubmed

• 10) Kumada M et al:Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046-2049, 2004
  pubmed

• 11) Ouchi N et al:Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063, 2001

• 12) Lautamaki R et al:Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 56:881-886, 2007
  pubmed

P.133 掲載の参考文献

• 1) Shimabukuro M et al:Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88:3236-3240, 2003

• 2) Tan KC et al:Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89:765-769, 2004
  pubmed

• 3) Ouchi N et al:Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231-234, 2003
  pubmed

• 4) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. J Biol Chem 277:37487-37491, 2002
  pubmed

• 5) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002
  pubmed

• 6) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 7) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vas Biol 23:85-89, 2003

• 8) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 9) Frystyk J et al:Serum adiponectin is a predictor of coronary heart disease:a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92:571-576, 2007

• 10) Hattori Y et al:Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia 46:1543-1549, 2003
  pubmed

• 11) Xi W et al:Stimulated HSP90 binding to eNOS and activation of the PI3-Akt pathway contribute to globular adiponectin-induced NO production:Vasorelaxation in response to globular adiponectin. Biochem Biophys Res Commun 332:200-205, 2005
  pubmed

• 12) Chen H et al:Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021-45026, 2003
  pubmed

• 13) Ouchi N et al:Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296-1301, 2000
  pubmed

• 14) Kobashi C et al:Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97:1245-1252, 2005
  pubmed

• 15) Motoshima H et al:Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315:264-271, 2004
  pubmed

• 16) Kobayashi H et al:Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004
  pubmed

• 17) Lin LY et al:Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett 574:106-110, 2004
  pubmed

• 18) Hattori Y et al:Globular adiponectin activates nuclear factor-κ B in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. Diabetes Care 29:139-141, 2006

P.140 掲載の参考文献

• 1) Wellen KE, Hotamisligil GS:Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112:1785-1788, 2003
  pubmed

• 2) Weisberg SP et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003
  pubmed

• 3) Xu H et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003

• 4) Kamei N et al:Overexpression of monocyte chemoattract protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281:26602-26614, 2006

• 5) Nishimura S et al:Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes 56:1517-1526, 2007
  pubmed

• 6) Ouchi N et al:Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063, 2001

• 7) Ouchi N et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
  pubmed

• 8) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 9) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 10) Shibata R et al:Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J Biol Chem 279:28670-28674, 2004
  pubmed

• 11) Ouchi N et al:Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279:1304-1309, 2004
  pubmed

• 12) Brakenhielm E et al:Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101:2476-2481, 2004
  pubmed

• 13) Suganami E et al:Leptin stimulates ischemia-induced retinal neovascularization:possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 53:2443-2448, 2004
  pubmed

• 14) Sierra-Honigmann MR et al:Biological action of leptin as an angiogenic factor. Science 281:1683-1686, 1998
  pubmed

• 15) Seida A et al:Serum bFGF levels are reduced in Japanese overweight men and restored by a 6-month exercise education. Int J Obes Relat Metab Disord 27:1325-1331, 2003
  pubmed

• 16) Oike Y et al:Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med 11:400-408, 2005
  pubmed

• 17) Rupnick MA et al:Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 99:10730-10735, 2002
  pubmed

P.146 掲載の参考文献

• 1) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 2) Ouchi N et al :Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
  pubmed

• 3) Ouchi N et al:Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296-1301, 2000
  pubmed

• 4) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 5) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 6) Ohashi K et al:Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Arn Coll Cardiol 43:1195-1200, 2004

• 7) Iwashima Y et al :Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318-1323, 2004
  pubmed

• 8) Kumada M et al:Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046-2049, 2004
  pubmed

• 9) Ouchi N et al:Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279:1304-1309, 2004
  pubmed

• 10) Kobayashi H et al:Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004
  pubmed

• 11) Curat CA et al:From blood monocytes to adipose tissue-resident macrophages:induction of diapedesis by human mature adipocytes. Diabetse 53:1285-1292, 2004

• 12) Iwashima Y et al :Association of hypoadiponectinemia with smoking habit in men. Hypertension 45 (6):1094-1100, 2005
  pubmed

• 13) Ohashi K et al:Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47:1108-1116, 2006
  pubmed

• 14) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002
  pubmed

• 15) Shibata R et al:Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096-1103, 2005
  pubmed

P.152 掲載の参考文献

• 1) Dandona P et al :Inflammation:the link between insulin resistance, obesity and diabetes, Trends Immunol 25:4-7, 2004
  pubmed

• 2) Weisberg SP et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003
  pubmed

• 3) Xu H et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003

• 4) Ito A et al:Role of MAPK phosphatase-1 in the induction of monocyte chemoattractant protein-1 during the course of adipocyte hypertrophy. J Biol Chem 282:25445-25452, 2007
  pubmed

• 5) Maeda N et al:PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001

• 6) Fasshauer M et al:Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084-1089, 2002
  pubmed

• 7) Fasshauer M et al:Adiponectin gene expressionand secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 301:1045-1050, 2003

• 8) Furukawa S et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
  pubmed

• 9) Ozcan U et al:Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461, 2004
  pubmed

• 10) Suganami T et al:A paracrine loop between adipocytes and macrophages aggravates inflammatory changes:role of free fatty acids and tumor necrosis factor α. Arterioscler Thromb Vasc Biol 25:2062-2068, 2005

• 11) Weisberg SP et al:CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115124, 2006

• 12) Kamei N et al:Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 281:26602-26614, 2006
  pubmed

• 13) Kanda H et al:MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494-1505, 2006

• 14) Suganami T et al:Role of the Toll-like receptor 4/NF κ B pathway in saturated fatty acid induced inflammatory changes in the interaction between adipocytes and macrophages. Arteriolscler Thromb Vasc Biol 27:84-91, 2007

• 15) Suganami T et al:Attenuation of obesity induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun 354:45-49, 2007
  pubmed

• 16) Poggi M et al:C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 50:1267-1276, 2007
  pubmed

• 17) Lumeng CN et al:Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117:175-184, 2007
  pubmed

• 18) Odegaard JI et al:Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447:1116-1120, 2007

• 19) Hevener AL et al:Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658-1669, 2007

• 20) Lee JY et al:Differential modulation of Toll-like receptors by fatty acids:preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res 44:479-486, 2003

• 21) Kris-Etherton PM et al:Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757, 2002
  pubmed

• 22) Yokoyama M et al:Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS):a randomised open-label, blinded endpoint analysis. Lancet 369:1090-1098, 2007
  pubmed

• 23) Itoh M et al:Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 27:1918-1925, 2007
  pubmed

• 24) Cinti S et al:Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 46:2347-2355, 2005
  pubmed

P.160 掲載の参考文献

• 1) Yokota T et al:Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (5):1723-1732, 2000
  pubmed

• 2) Wulster-Radcliffe MC et al:Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316:924-929, 2004
  pubmed

• 3) Wolf AM et al:Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 323:630-635, 2004
  pubmed

• 4) Fruebis J et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98 (4):2005-2010, 2001
  pubmed

• 5) Waki H et al:Generation of globular fragment of adiponectin by leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology 146 (2):790-796, 2005
  pubmed

• 6) Tsatsanis C et al:Adiponectin induces TNF-α and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun 335:1254-1263, 2005

• 7) Yamaguchi N et al:Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 579:6821-6826, 2005
  pubmed

• 8) Hattori Y et al:Globular adiponectin activates nuclear factor-κ B in vascular endothelial cells, which in turn induces expression of proinflammatory and adhesion molecule genes. Diabetes Care 29 (1):139-141, 2006

• 9) Park PH et al:Short-term treatment of RAW264.7 macrophages with adiponectin increases TNF-α expression via ERK1/2 activation and EGR-1 expression:role of TNF-α in adiponectin-stimulated IL-10 production. J Biol Chem 282 (30):21695-21703, 2007

• 10) Kumada M et al :Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046-2049, 2004
  pubmed

• 11) Saijo S et al:Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun 334:1180-1183, 2005
  pubmed

• 12) Takemura Y et al:Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 117 (2):375-386 , 2007
  pubmed

• 13) Foster SL et al:Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447:972-978, 2007

• 14) McGee SL, Hargreaves M :Exercise and skeletal muscle glucose transporter 4 expression:Molecular mechanisms. Clin Exp Pharmacol Physiol 33:395-399, 2006
  pubmed

P.166 掲載の参考文献

• 1) Richards JB et al:Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92:1517-1523, 2007
  pubmed

• 2) Jurimae J, Jurimae T:Adiponectin is a predictor of bone mineral density in middle-aged pre- menopausal women. Osteoporos Int 18:1253-1259, 2007

• 3) Peng XD et al:Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 387:31-35, 2008
  pubmed

• 4) Lee WY et al:Identification of adiponectin and its receptors in human osteoblast-like cells and association of T45G polymorphism in exon 2 of adiponectin gene with lumbar spine bone mineral density in Korean women. Clin Endocrinol (Oxf) 65:631-637, 2006
  pubmed

• 5) Kontogianni MD et al:Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546-551, 2004

• 6) Chanprasertyothin S et al:Relationship of body composition and circulatory adiponectin to bone mineral density in young premenopausal women. J Med Assoc Thai 89:1579-1583, 2006
  pubmed

• 7) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 8) Ogata N et al:Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 105:935-943, 2000
  pubmed

• 9) Akune T et al:Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 159:147-156, 2002
  pubmed

• 10) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 11) Yamauchi T et al:Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord 3:243-254, 2003
  pubmed

• 12) Shinoda Y et al :Regulation of bone formation by adiponectin through autocrine/paracrine andendocrine pathways. J Cell Biochem 99:196-208, 2006
  pubmed

• 13) Luo XH et al :Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway, Exp Cell Res 309:99-109, 2005
  pubmed

• 14) 0shima K et al:Adiponect in increases bone mass by suppressing osteoblast and activating osteoblast. Biochem Biophys Res Commun 331:520-526, 2005

• 15) Luo XH et al:Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648-1656, 2006
  pubmed

P.174 掲載の参考文献

• 1) Shibata R et al:Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J Biol Chem 279:28670-28674, 2004
  pubmed

• 2) Ouchi N et al:Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279:1304-1309, 2004
  pubmed

• 3) Luo XH et al:Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309:99-109, 2005
  pubmed

• 4) Hattori Y et al:Globular adiponectin activates nuclear factor-kB and activating protein-1 and enhances angiotensin II-induced proliferation in cardiac fibroblasts. Diabetes 56:804-808, 2007

• 5) DiMascio L et al:Identification of adiponectin as a novel hemopoietic stem cell growth factor. J Immunol 178:3511-3520, 2007
  pubmed

• 6) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. J Biol Chem 277:37487-37491, 2002
  pubmed

• 7) Arita Y et al:Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893-2898, 2002
  pubmed

• 8) Kamada Y et al:Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-1807, 2003
  pubmed

• 9) Wang Y et al:Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280:18341-18347, 2005

• 10) Shibata R et al:Adiponectin-mediated modulaion of hypertrophic signals in the heart. Nat Med 10:1384-1389, 2004

• 11) Okamoto Y et al:An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32:47-50, 2000
  pubmed

• 12) Motoshima H et al:Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315:264-271, 2004
  pubmed

• 13) Wang C et al:Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 282:7991-7996, 2007
  pubmed

• 14) Bub JD et al:Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 340:1158-1166 , 2006
  pubmed

• 15) Miyazaki T et al:Adiponectin activates c-Jun H2-terminal kinase and inhibits signal transducer and activator of transcription 3. Biochem Biophys Res Commun 333:79-87, 2005

• 16) Brakenhielm E et al:Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101:2476-2481, 2004
  pubmed

• 17) Ding X et al:The roles of leptin and adiponectin:a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 166:1655-1669, 2005
  pubmed

• 18) Wang Y et al:Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462-11470, 2006
  pubmed

• 19) Yokota T et al:Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells. J Immuno 1171:5091-5099, 2003

• 20) Yokota T et al:Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the fuctions macrophages. Blood 96:1723-1732, 2000

• 21) Konturek PC et al :Effect of Adiponectin and Ghrelin on Apoptosis of Barrett Adenocarcinoma Cell Line. Dig Dis Sci 53:597-605, 2008
  pubmed

• 22) Rattan R et al:5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280:39582-39593, 2005
  pubmed

• 23) Savill J et al:A blast from the past:clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2:965-975, 2002
  pubmed

• 24) Takemura Y et al:Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 117:375-386, 2007
  pubmed

• 25) Saijo S et al:Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun 334:1180-1183, 2005
  pubmed

• 26) Shibata R et al:Adiponectin protects against myocardialischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096-1103, 2005

• 27) Kobayashi H et al:Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004
  pubmed

• 28) Lin LY et al :Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett 574:106-110, 2004
  pubmed

• 29) Wang Y et al:Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J Biol Chem 281:16391-16400, 2006
  pubmed

• 30) Wang Y et al:Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem 277:19521-19529, 2002
  pubmed

• 31) Berg AH et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953, 2001
  pubmed

• 32) Liu J et al:Role of JNK activation in apoptosis:A double-edged sword. Cell Res 15:3642, 2005

P.184 掲載の参考文献

• 1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 :286-289, 1996
  pubmed

• 2) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 3) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 4) Otabe S et al:Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocrinol Metab 293:E210-218, 2007
  pubmed

• 5) Combs TP et al:A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367-383, 2004
  pubmed

• 6) Hara K et al:Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357-1362, 2006
  pubmed

• 7) Tsuchida A et al :Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54:3358-3370, 2005
  pubmed

• 8) Brakenhielm E et al:Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101:2476-2481, 2004
  pubmed

• 9) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002
  pubmed

• 10) Ebinuma H et al:A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 372:47-53, 2006
  pubmed

• 11) Bluher M et al:Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 299:572-574, 2003
  pubmed

• 12) Weindruch R, Sohal RS:Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med 337:986-994, 1997

• 13) Masoro EJ:Caloric restriction and aging:an update. Exp Gerontol 35:299-305, 2000
  pubmed

• 14) Roth GS et al:Biomarkers of caloric restriction may predict longevity in humans. Science 297:811, 2002
  pubmed

• 15) Berg AH et al:ACRP30/adiponectin:an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13:84-89, 2002
  pubmed

• 16) Zhu M et al:Circulating adiponectin levels increase in rats on caloric restriction:the potential for insulin sensitization. Exp Gerontol 39:1049-1059, 2004
  pubmed

• 17) Zhu M et al:Adipogenic signaling in rat white adipose tissue:modulation by aging and calorie restriction. Exp Gerontol 42:733-744, 2007
  pubmed

• 18) Caruso C et al:Aging, longevity, inflammation, and cancer. Ann NY Acad Sci 1028:1-13, 2004
  pubmed

• 19) Schriner SE et al :Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308:1909-1911, 2005
  pubmed

• 20) Mitsui A et al:Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal 4:693-696, 2002
  pubmed

• 21) Orr WC, Sohal RS :Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster, Science 263:1128-1130, 1994
  pubmed

• 22) Parkes TL et al:Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat Genet 19:171-174, 1998

• 23) Ishii T et al:A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res 65:203-209, 2005
  pubmed

• 24) Baranowska B et al:Neuroendocrine control of metabolic homeostasis in Polish centenarians. J Physiol Pharmacol 57 (Suppl 6):55-61, 2006
  pubmed

• 25) Goldstein DJ:Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16:397-415, 1992
  pubmed

• 26) Christou NV et al:Surgery decreases long-termmortality, morbidity, and health care use in morbidly obese patients. Ann Surg 240:416-423; discussion 423-424, 2004

• 27) Adams KF et al:Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355:763-778, 2006

• 28) Jee SH et al:Body-mass index and mortality in Korean men and women. N Engl J Med 355:779-787, 2006
  pubmed

• 29) Willcox BJ et al:Midlife risk factors and healthy survival in men. JAMA 296:2343-2350, 2006
  pubmed

• 30) Willcox DC et al:Caloric restriction and human longevity:what can we learn from the Okinawans? Biogerontology 7:173-177, 2006
  pubmed

• 31) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 32) Ryo M et al:Adiponectin as a biomarker of thernetabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 33) Hotta K et al:Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001
  pubmed

• 34) Lindsay RS et al :Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
  pubmed

• 35) Hotta K et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 36) Yamamoto Y et al:Adiponectin, an adipocyte-derived protein, predicts future insulin resistance:two-year follow-up study in Japanese population. J Clin Endocrinol Metab 89 :87-90, 2004
  pubmed

• 37) Daimon M et al:Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population:the Funagata study. Diabetes Care 26:2015-2020, 2003
  pubmed

• 38) Nakashima R et al :Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 91:3873-3877 , 2006
  pubmed

• 39) Osei K et al:Plasma adiponectin levels in high risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes. Obes Res 13:179-185, 2005
  pubmed

• 40) Snijder MB et al:Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women:the hoorn study. Diabetes Care 29:2498-2503, 2006
  pubmed

• 41) Snehalatha C et al:Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26:3226-3229, 2003
  pubmed

• 42) Ouchi N et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
  pubmed

• 43) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 44) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 45) Nishizawa H et al:Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734-2741, 2002
  pubmed

• 46) Zoico E et al:Adipocytokines, fat distribution, and insulin resistance in elderly men and women. J Gerontol A Biol Sci Med Sci 59:M935-939, 2004
  pubmed

• 47) Chang AM, Halter JB:Aging and insulin secretion. Am J Physiol Endocrinol Metab 284:E7-12, 2003
  pubmed

• 48) Mφller N et al :Effects of ageing on insulin secretion and action. Horm Res 60:102-104, 2003

• 49) Slawik M, Vidal-Puig AJ:Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev 5:144-164, 2006
  pubmed

• 50) Cartwright MJ et al:Aging in adipocytes:potential impact of inherent, depot-specific mechanisms. Exp Gerontol 42:463-471, 2007
  pubmed

3. アディポネクチン受容体の発見とメカニズム

P.195 掲載の参考文献

• 1) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 2) Hara K et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002
  pubmed

• 3) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 4) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 5) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 6) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 7) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

P.200 掲載の参考文献

• 1) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 2) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 3) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 4) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 5) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278 :40352-40363, 2003
  pubmed

• 6) Hada Y et al:Selective purification and characterization of adiponectin multimer species from human plasma. Biochem Biophys Res Commun 356:487-493, 2007
  pubmed

• 7) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 8) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

• 9) Hug C et al:T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 101:10308-10313, 2004
  pubmed

• 10) Kahn BB et al:A MP-activated protein kinase:ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1:15-25, 2005

• 11) Lizcano JM et al:LKBI is a master kinase thatactivates 13 kinases of the AMPK subfamily, including MARK/PAR-1. Embo J 23:833-843, 2004

• 12) Hawley SA et al:Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2:9-19, 2005
  pubmed

• 13) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 14) Mao X et al:APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol 8:516-523, 2006
  pubmed

• 15) Miaczynska M et al:APPL proteins link Rab5 tonuclear signal transduction via an endosomal compartment. Cell 116:445-456, 2004

• 16) Cheng KK et al :Adiponectin-induced endothelial nitric oxide synthase activation and nitricoxide production are mediated by APPL1 inendothelial cells. Diabetes 56:1387-1394, 2007

• 17) Saito T et al:The interaction of Akt with APPL1 is required for insulin-stimulated Glut4 translocation. J Biol Chem 282:32280-32287, 2007
  pubmed

P.205 掲載の参考文献

• 1) Kahn CR et al:Insulin-receptor interaction in the obese-hyperglycemic mouse. A model of insulin resistance. J Biol Chem 248:244-250, 1973

• 2) Flier JS et al:Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190:63-65, 1975

• 3) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 4) Yatagai T et al:Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52:1274-1278, 2003
  pubmed

• 5) Tsuchida A et al:Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004
  pubmed

• 6) Inukai K et al:Regulation of adiponectin receptor gene expression in diabetic mice. Am J Physiol Endocrinol Metab 288:E876-E882 , 2005
  pubmed

• 7) Chang S P et al:Increase of adiponectin receptor gene expression by physical exercise in soleus muscle of obese Zucker rats. Eur J Appl Physiol 97:189-195, 2006
  pubmed

• 8) Tsuchida A et al:Peroxisome proliferator-activated receptor (PPAR) α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of activation of PPAR α, PPARγ, and their combination. Diabetes 54:3358-3370 , 2005

• 9) Huang H et al:The effect of exercise training on adiponectin receptor expression in KKAy obese/diabetic mice. J Endocrinol 189:643-653, 2006
  pubmed

• 10) Haluzik MM et al:Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-α agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 147:4517-4524, 2006

• 11) Zhang H et al:Changes in adiponectin and inflammatory genes in response to hormonal imbalances in female mice and exacerbation of depot selective visceral adiposity by high-fat diet:implications for insulin resistance. Endocrinology 148:5667-5679, 2007
  pubmed

• 12) Bullen JW Jr et al :Regulation of adiponectin and its receptors in response to development of diet-induced obesity in mice, Am J physiol Endocrinol Metab 292:E1079-E1086, 2007
  pubmed

• 13) Rasmussen MS et al:Adiponectin receptors in human adipose tissue:effects of obesity, weight loss, and fat depots. Obesity 14 :28-35, 2006
  pubmed

• 14) Nannipieri M et al:Pattern of expression of adiponectin receptors in human adipose tissue depots and its relation to the metabolic state. Int J Obes 31:1843-1848 , 2007

• 15) Bluher M et al:Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle:associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 91:2310-2316, 2006
  pubmed

• 16) Civitarese AE et al:Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 47:816-820, 2004
  pubmed

• 17) Anderson PD et al:Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 92:2272-2279 , 2007
  pubmed

• 18) Mistry T et al:The regulation of adiponectin receptors in human prostate cancer cell lines. Biochem Biophys Res Commun 348:832-838, 2006
  pubmed

• 19) Guo Z et al:Cardiac expression of adiponectin and its receptors in streptozotocin-induced diabetic rats. Metabolism 56:1363-1371, 2007
  pubmed

• 20) Shimizu A et al:Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metabolism 56:1478-1485, 2007

• 21) Mullen KL et al:Globular adiponectin resistance develops independently of impaired insulin-stimulated glucose transport in soleus muscle from high-fat-fed rats. Am J Physiol Endocrinol Metab 293:E83-E90, 2007
  pubmed

• 22) O'Leary VB et al:Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Arn J Physiol Endocrinol Metab 293:E421-E427, 2007

• 23) Kim MJ et al:Increased adiponectin receptor-1 expression in adipose tissue of impaired glucose-tolerant obese subjects during weight loss. Eur J Endocrinol 155:161-165, 2006
  pubmed

• 24) Chinetti G et al:Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear rcccptors PPAR α, PPARγ, and LXR. Biochem Biophys Res Commun 314:151-158, 2004

• 25) Sun X et al:Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Diabetologia 49:1303-1310, 2006

P.213 掲載の参考文献

• 1) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 2) Civitarese AE et al:Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia 47:816-820, 2004
  pubmed

• 3) Staiger H et al:Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 53:2195-2201, 2004
  pubmed

• 4) Wang H et al:Adiponectin receptor 1 gene (ADIPOR1)as a candidate for type 2 diabetes and insulin resistance. Diabetes 53:2132-2136, 2004
  pubmed

• 5) Hara K et al:Absence of an association between the polymorphisms in the genes encoding adiponectin receptors and type 2 diabetes. Diabetologia 48 :1307-1314, 2005
  pubmed

• 6) Damcott CM et al:Genetic variation in adiponectin receptor 1 and adiponectin receptor 2 is associated with type 2 diabetes in the Old Order Amish. Diabetes 54:2245-2250, 2005
  pubmed

• 7) Vaxillaire M et al:Genetic analysis of ADIPOR1 and ADIPOR2 candidate polymorphisms for type 2 diabetes in the Caucasian population. Diabetes 55:856-861, 2006
  pubmed

• 8) Liao YF et al:A ssociation of the +33371 A/G polymorphism in adiponectin receptor 2 gene with Type 2 diabetes in the Chinese population. J Endocrinol Invest 30:860-864, 2007

• 9) Qi L et al:Variations in adiponectin receptor genes and susceptibility to type 2 diabetes in women:a tagging-single nucleotide polymorphism haplotype analysis. Diabetes 56:1586-1591, 2007
  pubmed

• 10) Siitonen N et al:Association of sequence variations in the gene encoding adiponectin receptor 1 ADIPOR1)with body size and insulin levels. The Finnish Diabetes Prevention Study. Diabetologia 49:1795-1805, 2006
  pubmed

• 11) Collins SC et al:Adiponectin receptor genes:mutation screening in syndromes of insulin resistance and asociation studies for type 2 diabetes and metabolic traits in UK populations. Diabetologia 50:555-562, 2007

• 12) Stefan N et al:Polymorphisms in the geneencoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 48:2282-2291, 2005

• 13) Kantartzis K et al:The-8503 G/A polymorphismof the adiponectin receptor 1 gene is associatedwith insulin sensitivity dependent on adiposity. Diabetes Care 29:464, 2006

• 14) Crimmins NA et al:Adiponectin receptor 1 variants associated with lower insulin resistance in African Americans. Obesity(Silver Spring)15:1903-1907, 2007
  pubmed

• 15) Hu C et al:Relationship between adiponectinreceptor 1 gene-3881T/C variant and glucose metabolism in the Chinese. Zhonghua Yi Xue YiChuan Xue Za Zhi 24:27-30, 2007

• 16) Ruchat SM et al:Associations between glucose tolerance, insulin sensitivity and insulin secretion phenotypes and polymorphisms in adiponectin and adiponectin receptor genes in the Quebec Family Study. Diabet Med 25:400-406, 2008
  pubmed

• 17) Crimmins NA, Martin LJ:Polymorphisms in adiponectin receptor genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes Rev 8:419-423, 2007
  pubmed

P.219 掲載の参考文献

• 1) Yamauchi Y et al:Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002

• 2) Fruebis J et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increased fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001

• 3) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 4) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 5) Inukai K et al:Regulation of adiponectin receptor gene expression in diabetic mice. Am J Physiol Endocrinol Metab 288:E876-882, 2005
  pubmed

• 6) Tsuchida A et al:Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004
  pubmed

• 7) Tan GD et al:Changes in adiponectin receptor expression in muscle and adipose tissue of type 2 diabetic patients during rosiglitazone therapy. Diabetologia 48:1585-1589, 2005
  pubmed

• 8) Tsuchida A et al:Peroxisome Proliferator-Activated Receptor (PPAR)α Activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue. Diabetes 54:3358-3370, 2005

• 9) Huang H et al:The effect of exercise training on adiponectin receptor expression in KKAy obese/diabetic mice. J Endocrinol 189:643-653, 2006
  pubmed

• 10) Beylot M et al:Expression of the adiponectin receptors AdipoR2 and AdipoR2 in lean rats and in obese Zucker rats. Metabolism 55 :396-401, 2006
  pubmed

• 11) Fang X et al:Hyperglycemia-and hyperinsulinemia-induced alteration of adiponectin receptor expression and adiponectin effects in L6 myoblasts. J Mol Endocrinol 35:465-476, 2005
  pubmed

• 12) Bjursell M et al:Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56:583-593, 2007
  pubmed

• 13) Civitarese AE et al:Adiponectin receptors gene expression and insulin sensitivity in nondiabetic Mexican Americans with or without a family history of type diabetes. Diabetologia 47:81 820, 2004
  pubmed

• 14) Debard C et al:Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 47:917-925, 2004
  pubmed

• 15) Staiger H et al:Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 53:2195-2201

• 16) Kaser S et al:Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54:117-121, 2005
  pubmed

• 17) Bluher M et al:Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle:Associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 91:2310-2316, 2006
  pubmed

4. 疾患・病態とアディポネクチン

P.229 掲載の参考文献

• 1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 2) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Bioche Biophys Res Commun 257:79-83, 1999

P.236 掲載の参考文献

• 1) Scherer PE et al:A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
  pubmed

• 2) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996

• 3) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221 :286-296, 1996
  pubmed

• 4) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120:803-812, 1996
  pubmed

• 5) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 6) Matsuda M et al:Role of adiponectin in preventing vascular stenosis-the missing link of adipo-vascular axis. J Biol Chem 277:37487-37491, 2002

• 7) Arita Y et al :Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 8) Weyer C et al:Hyperadiponectinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001

• 9) Daimon M et al:Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population:the Funagata study. Diabetes Care 26:2015-2020, 2003
  pubmed

• 10) Kumada M et al:Association of Hypoadiponectinemia with Coronary Artery Disease in Men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 11) Iwashima Y et al:Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318-1323, 2004
  pubmed

• 12) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes:molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 13) Tsao TS et al:Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 278:50810-50817, 2003
  pubmed

• 14) Pajvani UB et al :Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 15) Hada Y et al:Selective purification and characterization of adiponectin multimer species from human plasma. Biochem Biophys Res Commun 356:487-493, 2007
  pubmed

• 16) Kobayashi H et al:Selective suppression ofendothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004

• 17) Pajvani UB et al:Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement ininsulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

• 18) Ebinuma H et al:A novel ELISA system forselective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 372:47-53, 2006
  pubmed

• 19) Hara K et al:Measurement of the high-molecular-weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357-1362, 2006
  pubmed

• 20) Qi Y et al:Adiponectin acts in the brain to decrease body weight. Nat Med 10:524-529, 2004
  pubmed

• 21) Kusminski CM et al :Adiponectin complexes i nhuman cerebrospinal fluid:distinct complex distribution from serum. Diabetologia 50:634-642, 2007

• 22) Kubota N et al:Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55-68, 2007
  pubmed

• 23) Ebinuma H et al:Improved ELISA for selective measurement of adiponectin multimers and identification of adiponectin in human cerebrospinal fluid. Clin Chem 53:1541-1544, 2007
  pubmed

P.241 掲載の参考文献

• 1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 2) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 3) A sayama K et al:Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res 11:1072-1079 , 2003

• 4) Taksali SE et al:High visceral and low abdominal subcutaneous fat stores in the obese adolescent:A determinant of an adverse metabolic phenotype. Diabetes 57:367-371, 2008
  pubmed

• 5) Maeda N et al:PPARγ ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001

• 6) Hotta K et al :Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001
  pubmed

• 7) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 8) Qi Y et al:Adiponectin acts in the brain to decrease body weight. Nat Med 10 :524-529, 2004
  pubmed

• 9) Kubota N et al:Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 6:55-68, 2007
  pubmed

• 10) Diker D et al:Impact of gastric banding on plasma adiponectin levels. Obes Surg 16:1057-1061, 2006
  pubmed

• 11) Vendrell J et al:Resistin, adiponectin, ghrelin , and proinflammatory cytokines:relationships in obesity. Obes Res 12:962-971, 2004
  pubmed

• 12) Kopp HP et al:Effects of marked weight loss o nplasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes 29:766-771, 2005

• 13) Hulver MW et al:Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 283:E861-865 , 2002

• 14) Kriketos AD et al:Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 27:629-630, 2004
  pubmed

• 15) Polak J et al:Effect of aerobic training on plasma levels and subcutaneous abdominal adipose tissue gene expression of adiponectin, leptin, interleukin 6, and tumor necrosis factor alpha in obese women. Metabolism 55:1375-1381, 2006
  pubmed

• 16) Kondo T et al:Effect of exercise on circulating adipokine levels in obese young women. Endocr J 53:189-195, 2006
  pubmed

• 17) Esposito K et al:E ffect of weight loss and lifestyle changes on vascular inflammatory markers in obese women:a randomized trial. JAMA 289:1799-1804, 2003

P.249 掲載の参考文献

• 1) World Health Organization. Measuring obesity:classification and distribution of anthropometric data. WHO, Copenhagen, 1989. (Nutr UD, EUR/ICP/NUT 125)

• 2) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告. 糖尿病 42:385-401, 1999

• 3) Lindsay RS et al:Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
  pubmed

• 4) Krakoff J et al:Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745-1751, 2003
  pubmed

• 5) Daimon M et al:Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population:the Funagata study. Diabetes Care 26:2015-2020, 2003
  pubmed

• 6) Duncan BB et al:Adiponectin and the development of type 2 diabetes:the atherosclerosis risk in communities study. Diabetes 53:2473-2478, 2004
  pubmed

• 7) Snehalatha C et al:Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 26:3226-3229, 2003
  pubmed

• 8) Spranger J et al:Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226-228, 2003
  pubmed

• 9) Nakashima R et al:Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 91:3873-3877, 2006
  pubmed

P.255 掲載の参考文献

• 1) Shulman GI:Cellular mechanisms of insulin resistance. J Clin Invest 106 (2):171-176, 2000
  pubmed

• 2) Hotta K et al :Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50 (5):1126-1133, 2001
  pubmed

• 3) Lindsay et al :Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360 (9326):57-58, 2002
  pubmed

• 4) Maeda N et al :Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (7):731-737, 2002
  pubmed

• 5) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (1):85-89, 2003
  pubmed

• 6) Okamoto Y et al:An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32 (2):47-50, 2000
  pubmed

• 7) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipovascular axis. J Biol Chem 277 (40):37487-37491, 2002

• 8) Yuan M et al:Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673-1677, 2001
  pubmed

• 9) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (8):941-946, 2001
  pubmed

• 10) Fruebis J et al:Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98:2005-2010, 2001
  pubmed

• 11) Berg AH et al:The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (8):947-953, 2001
  pubmed

• 12) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (11):1288-1295, 2002
  pubmed

• 13) Wong GW et al:A family of Acrp30/adiponectin structural and functional paralogs. Proc Natl Acad Sci USA 101 (28):10302-10307, 2004
  pubmed

• 14) Bocher V et al:PPARs:transcription factors controlling lipid and lipoprotein metabolism. Ann NY Acad Sci 967:7-18, 2002
  pubmed

• 15) Zhang B et al:Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA 89:7541-7545, 1992
  pubmed

• 16) Gulick T et al:The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91:11012-11016, 1994
  pubmed

• 17) Muerhoff AS et al:The peroxisome proliferator-activated receptor mediates the induction of CYP4A6, a cytochrome P450 fatty acid omega-hydroxylase, by clofibric acid. J Biol Chem 267:19051-19053, 1992
  pubmed

• 18) Martin G et al:Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 272:28210-28217, 1997
  pubmed

• 19) Schoonjans K et al:Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem 270:19269-19276, 1995

• 20) Berthou L et al:Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids. Eur J Biochem 232:179-187, 1995
  pubmed

• 21) Malmendier CL, Delcroix C:Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Athrosclerosis 55:161-169, 1985

• 22) Staels B et al:Regulation of apo A-I gene expression by fibrates. Athrosclerosis 137 (Supp1. ):S19-23, 1998

• 23) Staels B et al :Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95 (2):705-712, 1995
  pubmed

• 24) Staels B, Auwerx J:Perturbation of developmental gene expression in rat liver by fibric acid derivatives:lipoprotein lipase and alpha-fetoprotein as models. Development 115:1035-1043, 1992
  pubmed

• 25) Murphy MC et al:Pretranslational regulation of the expression of the lipoprotein lipase (EC 3. 1. 1. 34) gene by dietary fatty acids in the rat. Br J Nutr 70:727-736, 1993
  pubmed

• 26) Schoonjans K et al:PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348, 1996

• 27) Keech A et al:Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial. Lancet 366 (9500):1849-1861, 2005

• 28) Meirhaeghe A et al:Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non. insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 24:195-199, 2000
  pubmed

• 29) Okuno A et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
  pubmed

• 30) Yamauchi T et al:The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 276:41245-41254, 2001
  pubmed

• 31) Chen Z et al:Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice:pleiotropic effects on CD36 expression and HDL Arterioscler Thromb Vasc Biol 21 (3):372-377, 2001
  pubmed

• 32) Chawla A et al:A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171, 2001
  pubmed

• 33) Yamauchi T et al:Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013, 2001
  pubmed

• 34) Tsuchida A et al:Peroxisome proliferator-activated receptor(PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of activation of PPARalpha, PPARgamma, and their combination, Diabetes 54 (12):3358-3370, 2005
  pubmed

• 35) Kubota N et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem 281 (13):8748-8755, 2006
  pubmed

• 36) Deeg MA et al:Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30:2458-2464, 2007
  pubmed

• 37) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366 (9493):1279-1289, 2005
  pubmed

• 38) Lazar MA:Progress in cardiovascular biology:PPAR for the course. Nat Med 7:23-24, 2001
  pubmed

• 39) Tontonoz P et al:PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998
  pubmed

• 40) Moore KJ et al:The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47, 2001
  pubmed

• 41) Chinetti G et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001
  pubmed

• 42) Oliver WR Jr et al:Ase lective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311, 2001

• 43) Akiyama TE et al:Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22:2607-2619, 2002
  pubmed

• 44) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 45) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic action. Nat Med 13:332-339, 2007

• 46) Koh KK et al:Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28:1419-1424, 2005
  pubmed

• 47) Inaba T et al:Cholesterol reduction and atherosclerosis of inhibition by bezafibrate in low desity lipoprotein receptor knockout mice. Hypertens Res (in press)

• 48) Narasimhan ML et al:Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17 (2):171-180, 2005 (Erratum in:Mol Cell 17 (4):611, 2005)

P.263 掲載の参考文献

• 1) Han SH et al:Adiponectin and cardiovascular disease:response to therapeutic interventions. J Arn Coll Cardiol 49:531-538, 2007

• 2) Adamczak M et al:Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 16:72-75, 2003
  pubmed

• 3) Iwashima Y et al:Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318-1323, 2004
  pubmed

• 4) 磯部健ほか:高齢者におけるアディポネクチンと 冠動脈危険因子との関連-端野・壮瞥町研究-. 日本老年医学会雑誌 41:328-333, 2004

• 5) Higashiura K et al:Correlations of adiponectin level with insulin resistance and atherosclerosis in Japanese male populations. Clin Endocrinol (Oxf) 61:753-759, 2004
  pubmed

• 6) Ohashi K et al:Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47:1108-1116, 2006
  pubmed

• 7) Kondo H et al:Association of adiponectin mutation with type 2 diabetes:a candidate gene for the insulin resistance syndrome. Diabetes 51:2325-2328, 2002
  pubmed

• 8) Buzzetti R et al:The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur J Hum Genet 12:1050-1054, 2004
  pubmed

• 9) Ouchi N et al:Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231-234, 2003
  pubmed

• 10) Ouchi N et al:Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279:1304-1309, 2004
  pubmed

• 11) Furuhashi M et al:Low adiponectin level in young normotensive men with a family history of essential hypertension. Hypertens Res 28:141-146, 2005
  pubmed

• 12) Murakami H et al:Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res 26:705-710, 2003
  pubmed

• 13) Arita Y et al:Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893-2898, 2002
  pubmed

P.267 掲載の参考文献

• 1) International Diabetes Federation. Worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_syndrome_definition.pdf.Accessed August 24, 2005

• 2) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日本内科学会雑誌 94:794-809, 2005

• 3) Matsuzawa Y et al:Adiponectin and metabolic syndrome. Aeterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 4) Ryo M et al:Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 5) Ohashi K et al:Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 27:1910-1917, 2007
  pubmed

• 6) Kamada Y et al:Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J Hepatol 47:556-564, 2007

• 7) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most Abundant Gene Transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 8) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 9) Choi KM et al:Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol 61(1):75-80, 2004
  pubmed

• 10) Hara K et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002
  pubmed

• 11) Vasseur F et al:Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponedctin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Mol Genet 11:2607-2614, 2002

• 12) Kondo H et al:Association of adiponectin mutation with type 2 diabetes:acandidate gene for the insulin resistance syndrome. Diabetes 51:2325-2328, 2002

• 13) Iwashima Y et al:Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98:1603-1608, 2006
  pubmed

P.277 掲載の参考文献

• 1) Matteoni CA et al:Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999
  pubmed

• 2) 日本肝臓学会:NASH. NAFLDの診療ガイド, 文光堂, 東京, 2006

• 3) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 4) Hotta K et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 5) Hui JM et al:Beyond insulin resistancc in NASH:TNF-alpha or adiponectin? Hepatology 40:46-54, 2004
  pubmed

• 6) Brunt EM:Nonalcoholic steatohepatitis. Semin Liver Dis 24:3-20, 2004
  pubmed

• 7) Ratziu V et al:Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128:1898-1906, 2005
  pubmed

• 8) Marrero JA et al:NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36:1349-1354, 2002
  pubmed

• 9) Bugianesi E et al:Expanding the natural history of nonalcoholic steatohepatitis:from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134-140, 2002
  pubmed

• 10) Maeda N et al:Diet-illduced insulill resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 11) Ouchi N et al:Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296-1301, 2000
  pubmed

• 12) Kamada Y et al:Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-1807, 2003
  pubmed

• 13) Enomoto N et al:Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production. Gastroenterology 123:291-300, 2002
  pubmed

• 14) Hourigan LF et al:Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29:1215-1219, 1999
  pubmed

• 15) Patton HM et al:The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40:484-490, 2004
  pubmed

• 16) Inoue M et al:Diabetes mellitus and the risk ofcancer:results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871-1877, 2006

• 17) Moriya K et al:Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61:4365-4370, 2001

• 18) Kelesidis I et al:Adiponectin and cancer:a systematic review. Br J Cancer 94:1221-1225, 2006

• 19) Calle EE et al:Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 348:1625-1638, 2003

• 20) Yanagitani A et al:Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 40:366-375, 2004
  pubmed

• 21) Horie Y et al:Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113:1774-1783, 2004
  pubmed

• 22) Deng QG et al:Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42:905-914, 2005
  pubmed

• 23) Dixon JB et al:Nonalcoholic fatty liver disease:Improvement in liver histological analysis with weight loss. Hepatology 39:1647-1654, 2004
  pubmed

• 24) Lavine JE:Vitamin E treatment of nonalcoholic steatohepatitis in children:a pilot study. J Pediatr 136:734-738, 2000
  pubmed

• 25) Bugianesi E et al:A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082-1090, 2005
  pubmed

• 26) Kubota N et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectindependent and-independent pathways. J Biol Chem 281:8748-8755, 2006
  pubmed

• 27) Promrat K et al:Apilot study of pioglitazonetreatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004

• 28) Ip E et al:Administration of the potent PPARalpha agonist, Wy-14, 643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 39:1286-1296, 2004
  pubmed

• 29) Saibara T et al:Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 353:1802, 1999
  pubmed

• 30) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

P.281 掲載の参考文献

• 1) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 2) Hotta K et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599 , 2000
  pubmed

• 3) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 4) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 5) Ouchi N et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100 :2473-2476, 1999
  pubmed

• 6) Ouchi N et al:Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063, 2001

• 7) Arita Y et al:Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105:2893-2898, 2002
  pubmed

• 8) Okamoto Y et al:Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice. Circulation 106:2767-2770, 2002
  pubmed

• 9) Kobayashi H et al:Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004
  pubmed

• 10) Kumada M et al:Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 109:2046-2049, 2004
  pubmed

• 11) Ouchi N et al:Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue, Circulation 107 :671-674, 2003
  pubmed

• 12) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
  pubmed

• 13) Hiuge A et al:Effects of Peroxisome Proliferator-Activated Receptor Ligands, Bezafibrate and Fenofibrate, on Adiponectin Level. Arterioscler Thromb Vasc Biol 27:635-641, 2007
  pubmed

• 14) Kurata A et al:Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tis sue and ameliorates adipocytokine dysregulation. Kidney Int 70:1717-1724, 2006

• 15) Sugiyama S et al:Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194:e43-51, 2007
  pubmed

• 16) Iwashima Y et al:Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318-1323, 2004
  pubmed

P.289 掲載の参考文献

• 1) Matsuzawa Y et al:Adionectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004

• 2) Ouchi N et al:Novel modulator for endotherial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999

• 3) Hotta K et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Artescler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 4) Ad Hoc Commitiee of National Insitute of Neurological Disorders and Stroke:Classification of Cerbrovascular Disease III. Stroke 21:637-676, 1990

• 5) Yamashiro K et al:Clustering of risk factors increases the incidence of echolucent carotid plaqtle in stroke patients. Cerebrovasc Dis 22:432-438, 2006
  pubmed

• 6) Milionis HJ et al:Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 36:1372-1376, 2005
  pubmed

• 7) Ninomiya T et al:Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population. The Hisayama Study. Stroke 38:2063-2069, 2007

• 8) Kubo M et al:Decreasing incidence of lacunar vs other types of cerebral infarction in a Japanese population. Neurology 66:1539-1544, 2006

• 9) Rost NS et al:Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. The Framingham study. Stroke 32:2575-2579, 2001
  pubmed

• 10) Soderberg S et al:Leptin, but not adiponectin, predicts stroke in males. J Intern Med 256:18-136, 2004

• 11) Chen MP et al:Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25:821-826, 2005
  pubmed

• 12) Efstathiou SP et al:Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36:1915-1919, 2005
  pubmed

• 13) Bang OY et al:Adiponectin levels in patients with intracranial atherosclerosis. Neurology 68:1931-1937, 2007
  pubmed

• 14) Wannamethee SG et al:The metabolic syndrome and insulin resistance:relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 181:101-108, 2005
  pubmed

• 15) Kato H et al:Adiponectin acts as an endogenousantithrombotic factor. Arterioscler ThrombVasc Biol 26:224-230, 2006
  pubmed

• 16) Shibata R et al:Adiponectin protects againstmyocardial ischemia-reperfusion injury through AMPK-and COX2-dependent mechanisms. Nat Med 11:1096-1103, 2005

• 17) Yu JG et al:The effect of thiazolidinediones o nplasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968-2974, 2002

P.293 掲載の参考文献

• 1) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 2) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 3) Funahashi T, Matsuzawa Y:Hypoadiponectinemia:a common basis for diseases associated with overnutrition. Curr Atheroscler Rep 8:433-438, 2006
  pubmed

• 4) Bajaj M, Ben-Yehuda O:A big fat wedding:association of adiponectin with coronary vascular lesions. J Am Coll Cardiol 48:1163-1165, 2006
  pubmed

• 5) Hara K et al:Reduced adiponectin level is associated with severity of coronary artery disease. Int Heart J 48:149-153, 2007
  pubmed

• 6) Ohashi K et al:Adiponectin I164T mutation isassociated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 43:1195-1200, 2004

• 7) Filippi E et al: The adiponectin gene SNP+276G>T associates with early-onset coronary artery disease and with lower levels ofadiponectin in younger coronary artery diseasepatients (age <or=50 years). J Mol Med 83:711-719, 2005

• 8) Cavusoglu E et al:Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27:2300-2309, 2006
  pubmed

• 9) Pilz S et al:Adiponectin and mortality in patients undergoing coronary angiography. J Clin Endocrinol Metab 91:4277-4286, 2006
  pubmed

• 10) Kanaya AM et al:Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 91:5044-5050, 2006
  pubmed

• 11) Tentolouris N et al:Plasma adiponectin concentrations in patients with chronic renal failure:relationship with metabolic risk factors and ischemic heart disease. Horm Metab Res 36:721-727, 2004
  pubmed

• 12) Kobayashi H et al:Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 94:e27-31, 2004
  pubmed

• 13) Inoue T et al:High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol 100:569-574, 2007
  pubmed

• 14) Ouchi N, Walsh K:Adiponectin as an anti-inflammatory factor. Clin Chim Acta 380:24-30, 2007
  pubmed

• 15) Katagiri H et al:Adiposity and cardiovascular disorders:disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 101:27-39, 2007
  pubmed

• 16) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002
  pubmed

• 17) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 18) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 19) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487-37491, 2002

• 20) Chen H et al:Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021-45026, 2003
  pubmed

• 21) Ouchi N et al:Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231-234, 2003
  pubmed

• 22) Kobashi C et al:Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97:1245-1252, 2005
  pubmed

• 23) Ouchi N et al:Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296-1301, 2000
  pubmed

• 24) Yamaguchi N et al:Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 579:6821-6826, 2005
  pubmed

• 25) Okamoto Y et al:Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocytes recruitment in atherogenesis. Circ Res 102:218-225, 2008
  pubmed

• 26) Cheng KKY et al:Adiponectin-induced endothelial nitric oxide synthase activation and nitric oxide production are mediated by APPL1 in endothelial cells. Diabetes 56:1387-1394, 2007

• 27) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

• 28) Shibata R et al:Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096-1103, 2005
  pubmed

• 29) Fujioka D et al:Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol 290:H2409-2416, 2006
  pubmed

• 30) Saito Y et al:Statin reverses reduction of adiponectin receptor expression in infarcted heart and in TNF-alpha-treated cardiomyocytes in association with improved glucose uptake. Am J Physiol Heart Circ Physiol 293:H3490-3497, 2007
  pubmed

• 31) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial Lancet 366:1279-1289, 2005
  pubmed

• 32) Kadowaki T, Yamauchi T:Adiponectin and adiponectin receptors. Endocr Rev 26:439-451, 2005
  pubmed

P.297 掲載の参考文献

• 1) Levy D et al:Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561-1566, 1990
  pubmed

• 2) Okin PM et al:LIFE Study Investigators:Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension 44:48-54, 2004

• 3) Sega R et al:Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population:follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111:1777-1783, 2005
  pubmed

• 4) Avelar E et al:Left ventricular hypertrophy in severe obesity:interactions among blood pressure, nocturnal hypoxemia, and body mass. Hypertension 49:34-39, 2007
  pubmed

• 5) Ilercil A et al:Relationship of impaired glucose tolerance to left ventricular structure and function:The Strong Heart Study. Am Heart J 141:992-998, 2001
  pubmed

• 6) McGavock JM et al:American College of Physicians and the American Physiological Society. Adiposity of the heart, revisited. Ann Intern Med 144:517-524, 2006
  pubmed

• 7) Smilde TD et al:Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. Am J Hypertens 18:342-347, 2005
  pubmed

• 8) Iwashima Y et al:Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318-1323, 2004
  pubmed

• 9) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed

• 10) Matsushita K et al:Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 26:871-876, 2006
  pubmed

• 11) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 12) Lopaschuk GD et al:Cardiac energy metabolism in obesity. Circ Res 101:335-347, 2007
  pubmed

• 13) Shibata R et al:Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 10:1384-1389, 2004
  pubmed

• 14) Liao Y et al:Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 67:705-713, 2005
  pubmed

• 15) Tao L et al:Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115:1408-1416, 2007
  pubmed

• 16) Tamura T et al:Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure. Circ J 71:623-630, 2007
  pubmed

• 17) Hong SJ et al:Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press 13:236-242, 2004
  pubmed

• 18) Okin PM et al:LIFE Study Investigators:Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascularevents. JAMA 292:2343-2349, 2004

• 19) Mitsuhashi H et al:Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension 49:1448-1454, 2007
  pubmed

• 20) Vahanian A et al:ESC GUIDELINES DESK REFERENCE. London, Lippincott Williams & Wilkins, 2007, p 19

• 21) Babiker FA et al:Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26:1524-1530, 2006
  pubmed

• 22) Tamakoshi K et al:The transition to menopause reinforces adiponectin production and its contribution to improvement of insulin-resistant state. Clin Endocrinol 66:65-71, 2007
  pubmed

P.304 掲載の参考文献

• 1) National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification. Am J Kidney Dis 39:S1-266, 2002
  pubmed

• 2) Imai E ct al:Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41-50, 2007

• 3) Hillege HL et al:Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population. Circulation 106:1777-1782, 2002
  pubmed

• 4) Manjunath G et al:Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41:47-55, 2003
  pubmed

• 5) Irie F et al:The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264-1271, 2006
  pubmed

• 6) Nonomiya T et al:Chronic kidney disease and cardiovascular disease in a general Japanese population:the Hisayama Study. Kidney Int 68:228-236, 2005

• 7) Adler AI et al:Development and progression of nephropathy in type 2 diabetes:the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63:225-232, 2003
  pubmed

• 8) Nakamura A et al:Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 28:2890-2895, 2005
  pubmed

• 9) 図説わが国の慢性透析療法の現況 (2006年12月31日現在). 日本透析医学会, 2007

• 10) Parving HH et al:Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients:aglobal perspective. Kidney Int 69:2057-2063, 2006

• 11) Yokoyama H et al:Microalbuminuria is common in Japanese type 2 diabetic patients:a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care 30:989-992, 2007

• 12) Becker B et al:Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease:the mild and moderate kidney disease study. J Am Soc Nephrol 16:1091-1098, 2005
  pubmed

• 13) Menon V et al:Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17:2599-2606, 2006
  pubmed

• 14) Iwashima Y et al:Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98:1603-1608, 2006
  pubmed

• 15) Mitsnefes M et al:Adiponectin in children with chronic kidney disease:role of adiposity and kidney dysfunction. Clin J Am Soc Nephrol 2:46-50, 2007
  pubmed

• 16) Koshimura J et al:Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun 316:165-169, 2004
  pubmed

• 17) Stenvinkel P et al:Adiponectin in renal disease:relationship to phenotype and genetic variation in the gene encoding adiponectin. Kidney Int 65:274-281, 2004
  pubmed

• 18) Shoji T et al:Molecular forms of adiponectin in uraemic plasma. Nephrol Dial Transplant 19:1937-1938, 2004

• 19) Shen YY et al:Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Nephrol Dial Transplant 22:171-178, 2007
  pubmed

• 20) Marchlewska A et al:Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. Kidney Int 66:46-50, 2004
  pubmed

• 21) Barazzoni R et al:Low fat adiponectin expression is associated with oxidative stress in nondiabetic humans with chronic kidney disease-impact on plasma adiponectin concentration. Am J Physiol Regul Integr Comp Physiol 293:R47-54, 2007
  pubmed

• 22) Saraheimo M et al:Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 28:1410-1414, 2005
  pubmed

• 23) Fujita H et al:Possible relationship between adiponectin and renal tubular injury in diabetic nephropathy. Endocr J 53:745-752, 2006
  pubmed

• 24) Komaba H:Increased serum high-molecular-weight complex of adiponectin in type 2 diabetic patients with impaired renal function. Am J Nephrol 26:476-482, 2006
  pubmed

• 25) Lin J:Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 30:239-244, 2007
  pubmed

• 26) Yilmaz MI et al:Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin. Nephrol Dial Transplant (in press)

• 27) Kollerits B et al:Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease:the Mild to Moderate Kidney Disease Study. Kidney Int 71:1279-1286, 2007
  pubmed

• 28) Ohashi K et al:Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 27:1910-1917, 2007
  pubmed

P.312 掲載の参考文献

• 1) 井口正典ほか:尿路結石症の発生原因に関する検討-夕食から就寝までの間隔が尿路結石症の発生に及ぼす影響について. 日泌会 80:1574-1578, 1989

• 2) Yasui T et al:Eicosapentaenoic acid[EPA] medically prevent the recurrence of urinary calculus. Urol Res 33:150, 2005

• 3) Taylor EN et al:0besity, weight gain, and the risk of kidney stones. JAMA 293 (4):455-462, 2005
  pubmed

• 4) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277:37487-37491, 2002

• 5) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767-2770, 2002
  pubmed

• 6) Itoh Y et al:Examination of the anti-oxidative effect in renal tubular cells and apoptosis by oxidative stress. Urol Res 33:261-266, 2005
  pubmed

• 7) Itoh Y et al:Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis. J Urol 173:271-275, 2005
  pubmed

P.319 掲載の参考文献

• 1) Binder BR et al:Plasminogen activator inhibitor 1:Physiological and pathophysiological roles. News Physiol Sci 17:56-61, 2002
  pubmed

• 2) Schneiderman J et al:Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:6998-7002, 1992
  pubmed

• 3) Zhu Y et al:Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice. Circulation 103:3105-3110, 2001
  pubmed

• 4) Yamamoto K, Saito H:A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 68:371-385, 1998
  pubmed

• 5) Landin K et al:Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor 1. Metabolism 39:1044-1048, 1990
  pubmed

• 6) Shimomura I et al:Enhanced expression of PAI-1 in visceral fat:Possible contributor to vascular disease in obesity. N at Med 2:800-803, 1996

• 7) Hoekstra T et al:Plasminogen activator inhibitor-type 1:its plasma determinants and relation with cardiovascular risk. Thromb Haemost 91:861-872, 2004
  pubmed

• 8) Zirlik A et al:Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 91:674-682, 2004
  pubmed

• 9) Juhan-Vague I et al:plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575-1579, 2003

• 10) Lijnen HR et al:On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice. J Thromb Haemost 3:1174-1179, 2005
  pubmed

• 11) Schafer K et al:Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15:1840-1842, 2001
  pubmed

• 12) Ma LJ et al:Prevention of obesity and insulin resistance in mice lacking Plasminogen activator inhibitor 1. Diabetes 53:336-346, 2004
  pubmed

• 13) Samad F et al:Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo:induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest 97:37-46, 1996

• 14) Liang X et al:Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 290:E103-113, 2006
  pubmed

• 15) Sawdey MS, Loskutoff DJ:Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth factor-β. J Clin Invest 88:1346-1353, 1991

• 16) Samad F et al:Elevated expression of transforming growth factor-β in adipose tissue from obese mice. Mol Med 3:37-48, 1997

• 17) Hotamisligil GS et al:Adipose expression of tumor necrosis factor-α:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993

• 18) Samad F et al:Tumor necrosis factorαis a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 96:6902-6907, 1999

• 19) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 20) Samad F, Loskutoff DJ:Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 2:568-582, 1996
  pubmed

• 21) Maruyoshi H et al:Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost 91:1026-1030, 2004
  pubmed

• 22) Mertens I et al:Inverse relationship between plasminogen activator inhibitor-1 activity and adiponectin in overweight and obese women. Thromb Haemost 94:1190-1195, 2005
  pubmed

• 23) Kato H et al:Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 26:224-230, 2006
  pubmed

• 24) Ouchi N et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
  pubmed

• 25) Kumada M et al:Coronary artery disease:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 26) Zoccali C et al:Adiponectin, metabolic risk facors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141, 2002

• 27) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 28) Shibata R et al:Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med 11:1096-1103, 2005
  pubmed

P.327 掲載の参考文献

• 1) Mantzoros C et al:Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89 (3):1102-1107, 2004

• 2) Miyoshi Y et al:Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9 (15):5699-5704, 2003
  pubmed

• 3) Petridou E et al:Plasma adiponectin concentrations in relation to endometrial cancer:a case-control study in Greece. J Clin Endocrinol Metab 88 (3):993-997, 2003

• 4) Cust AE et al:Plasma adiponectin levels and endometrial cancer risk in pre-and post-menopausal women. J Clin Endocrinol Metab 92 (1):255-263, 2007

• 5) Baillargeon J et al:Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 15 (7):1331-1335, 2006

• 6) Goktas S et al:Prostate cancer and adiponectin. Urology 65 (6):1168-1172, 2005
  pubmed

• 7) Freedland SJ et al:Association between serum adiponectin, and pathological stage and grade in men undergoing radical prostatectomy. J Urol 174 (4Pt 1):1266-1270, 2005

• 8) Ishikawa M et al:Plasma adiponectin and gastric cancer. Clin Cancer Res 11 (2 Pt 1):466-472, 2005
  pubmed

• 9) Wei EK et al:Low plasma adiponectin levels and risk of colorectal cancer in men:a prospective study. J Natl Cancer Inst 97 (22):1688-1694, 2005

• 10) Lukanova A et al:Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 15 (2):401-402, 2006

• 11) Petridou E et al:Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 94 (1):156-160, 2006
  pubmed

• 12) Kang JH et al:Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28 (11):1263-1269, 2005
  pubmed

• 13) Yokota T et al:Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (5):1723-1732, 2000
  pubmed

• 14) Dieudonne MN et al:Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 345 (1):271-279, 2006
  pubmed

• 15) Cong L et al:Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL952. Endocr Relat Cancer 14 (3):713-720, 2007

• 16) Ishikawa M et al:Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 98 (7):1120-1127, 2007
  pubmed

• 17) Luo Z et al:AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26 (2):69-76, 2005
  pubmed

• 18) Wang Y et al:Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 280 (18):18341-18347, 2005

• 19) Brakenhielm E et al:Adiponectin-inducedantiangiogenesis and antitumor activity involvecaspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 101 (8):2476-2481, 2004
  pubmed

• 20) Wulster-Radcliffe MC et al:Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 316 (3):924-929, 2004
  pubmed

P.333 掲載の参考文献

• 1) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 2) 門脇弘子:肥満とアディポサイトカイン. 小児内科 38 (9):1610-1614, 2006

• 3) Semple RK et al:Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 91:3219-3223, 2006
  pubmed

• 4) 門脇弘子:小児のアディポネクチン値. 日本小児科学会雑誌 108 (8):1056-1058, 2004

• 5) 門脇弘子:高分子量アディポネクチン測定とメタボリックシンドロームの診断. ホルモンと臨床 54:1011-1014, 2006

• 6) Kadowaki H et al:Mutagenesis of lysine 460 in the human insulin receptor. Effects upon receptor recycling and cooperative interactions among binding sites. J Biol Chem 265:21285-21296, 1990
  pubmed

• 7) Savage DB et al:Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31:379-384, 2002

• 8) Bogans JS, Lodish HF:Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol 146:609-620, 1999

• 9) Imagawa A et al:Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care 25:1665-1666, 2002
  pubmed

• 10) Lindsay RS et al:Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
  pubmed

• 11) Mohlig M et al:Insulin decreases human adiponectin plasma levels. Horm Metab Res 34:655-658, 2002
  pubmed

• 12) Hotta K et al:Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001
  pubmed

• 13) Pereira RI, Draznin B:Inhibition of the phosphatidylinositol 3-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes. Metabolism 54:1636-1643, 2005
  pubmed

• 14) Bluher M et al:Adipose tissue selective insulin receptor knockout protects against obesity andobesity-related glucose intolerance. Dev Cell 3:25-38, 2002

• 15) Cariou B et al:Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice. Endocrinology 145:1926-1932, 2004
  pubmed

• 16) Frystyk J et al:Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 48:1911-1918, 2005
  pubmed

• 17) Looker HC et al:Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 89:4010-4017, 2004
  pubmed

• 18) Semple RK et al:Plasma adiponectin as a marker of insulin receptor dysfunction. Clinical utilityin severe insulin resistance. Diabetes Care 31:977-979, 2008

5. アディポネクチン・受容体をターゲットとした薬物治療・生活習慣介入

P.343 掲載の参考文献

• 1) Lehmann JM et al:An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956, 1995
  pubmed

• 2) Okuno A et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
  pubmed

• 3) Xu H et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003

• 4) Weisberg SP et al:Obesity is associated with macrophage accumulation in adipose tissue J. Clin Invest 112:1796-1808, 2003
  pubmed

• 5) Scherer PE et al:A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
  pubmed

• 6) Maeda K et al:cDNA cloning and expression of anovel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996

• 7) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996

• 8) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 120:803-812, 1996
  pubmed

• 9) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 10) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 11) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003 Erratum in:Nature 431:1123, 2004

• 12) Hotta K et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 13) Ouchi N et al:Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063, 2001

• 14) Ouchi N et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
  pubmed

• 15) Iwaki M et al:Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003
  pubmed

• 16) Hirose H et al:Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314-317, 2002
  pubmed

• 17) Tonelli J et al:Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621-1629, 2004
  pubmed

• 18) Pajvani UB et al:Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

• 19) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 20) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/ adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 21) Kahn SE et al:Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443, 2006

• 22) The DREAM Trial Investigators:Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose:a randomized controlled trial. Lancet 368:1096-1105, 2006
  pubmed

• 23) Odegaard JI et al:Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 447:1116-1120, 2007

• 24) Hevener AL et al:Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 117:1658-1669, 2007

• 25) Kubota N et al:Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and-independent Pathways. J Biol Chem 281:8748-8755, 2006
  pubmed

• 26) Dormandy JA et al:Secondary prevention of macrovascular evellts in patiellts with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 27) Mazzone T et al:Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. JAMA 296:2572-2581, 2006
  pubmed

• 28) Deeg MA et al:Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30:2458-2464, 2007
  pubmed

• 29) Maeda N et al:Diet-induced insulin resistancein mice lacking adiponectin/ACRP30. Nat Med8:731-737, 2002

• 30) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 31) Kubota N et al:Disruption of adiponectin causesinsulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 32) Li AC et al:Peroxisome proliferator-activatedreceptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531, 2000

• 33) Chinetti G et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001
  pubmed

• 34) Chawla A et al:A PPAR-gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171, 2001
  pubmed

P.348 掲載の参考文献

• 1) Julius S et al:VALUE Trial:long-term blood pressure trends in 13, 499 patients with hypertension and high cardiovascular risk. Am J Hypertens 16:544-548, 2003

• 2) Dahlof B et al:Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):a randomised trial against atenolol. Lancet 359:995-1003, 2002
  pubmed

• 3) Mochizuki S et al:Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study):arandomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369:1431-1439, 2007

• 4) Fukui T et al:Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients:rationale, design, and methods. Hypertens Res 26:979-990, 2003

• 5) Aquirre V et al:The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with IRS-1 and phosphorylation of Ser(307). J Biol Chem 275:9047-9054, 2000

• 6) Katayama S et al:Is renoprotection by angiotensin receptor blocker dependent on blood pressure?:The Saitama Medical School, Albuminuria redeuction in diabetics with Valsartan (STAR) study. Hypertens Res 30:529-533, 2007
  pubmed

• 7) Furuhashi M et al:Blockade of the rennin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 42:76-81, 2003

• 8) Nielsen S et al:Increased plasma adiponectin in losartan-treated type 1 diabetic patients. a mediator of improved insulin sensitivity? Horm Metab Res 36:194-196, 2004
  pubmed

• 9) Mori Y et al:Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 24:146-153, 2007

• 10) Nomura S et al:Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 117:385-392, 2006
  pubmed

• 11) Furukawa S et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
  pubmed

• 12) Rueckschloss U et al:Dose-dependent regulation of NAD (P) H oxidase expression by angiotensin II in human endothelial cells:protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22:1845-1851, 2002
  pubmed

• 13) Schupp M et al:Angiotensin type 1 receptorblockers induce PPARgamrna activity. Circulation 109:2054-2057, 2004

• 14) Benson SC et al:Identification of Telmisartan asaunique angiotensin II receptor blocker antagonist with selective PPARgamma-modulatin gactivity. Hypertension 43:993-1002, 2004

• 15) Schupp M et al:Molecular characterization of new selective PPARgamma modulators with angiotensin receptor blocking activity. Diabetes 54:3442-3452, 2005
  pubmed

• 16) Miura Y et al:Replacement of valsartan and candesartan by telmisartan in hypertensive patientswith type 2 diabetes:metabolic and antiatherogenic consequences. Diabetes Care 28:757-758, 2005

• 17) Iwaki M et al:Induction of adiponectin, a fatderived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003

• 18) Araki K et al:Telmisartan prevents obesity and increase the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48:51-57, 2006
  pubmed

• 19) Sugimoto K et al:Telmisartan but not Valsartan increase caloric expenditure and protects against weight gain and hepatic steatosis. Hypertention 47:1003-1009, 2006

• 20) Imayama I et al:Telmisartan downregulates angiotensin II type 1 receptor through activation of PPARgamma. Cardiovasc Res 72:184-190, 2006
  pubmed

P.356 掲載の参考文献

• 1) Issemann I, Green S:Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347 (6294):645-650, 1990
  pubmed

• 2) Frick MH et al:Helsinki Heart Study:primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (20):1237-1245, 1987
  pubmed

• 3) Rubins HB et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 (6):410-418, 1999

• 4) The BIP study group:Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease:the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (1):21-27, 2000

• 5) Keech A et al:FIELD study investigators:Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):randomised controlled trial. Lancet 366 (9500):1849-1861, 2005

• 6) Hiuge A et al:Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27 (3):635-641, 2007
  pubmed

• 7) Tsuchida A et al:Peroxisome proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue:comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 54 (12):3358-3370, 2005
  pubmed

• 8) Loviscach M et al:Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue:relation to insulin action. Diabetologia 43 (3):304-311, 2000
  pubmed

• 9) Guzman M et al:Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 279 (27):27849-27854, 2004
  pubmed

• 10) Willson TM et al:The PPARs:from orphan receptors to drug discovery. J Med Chem 43 (4):527-550, 2000
  pubmed

• 11) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (9):2094-2099, 2001
  pubmed

• 12) Iwaki M et al:Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 (7):1655-1663, 2003
  pubmed

• 13) Koh KK et al:Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 28(6):1419-1424, 2005
  pubmed

• 14) Koh KK et al:Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (10):1649-1653, 2005
  pubmed

P.365 掲載の参考文献

• 1) Tsuchida A et al:lnsulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004

• 2) Tsuchida A et al:Peroxisome Proliferator-Activated Receptor(PPAR) α Activation Increases Adiponectin Receptors and Reduces Obesity-Related Inflammation in Adipose Tissue:Comparison of Activation of PPAR α, PPARγ and Their Combination. Diabetes 54:3358-3370, 2005

• 3) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 4) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 5) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 6) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 7) Narasimhan LM et al:Osmotin is a Homolog of Human Adiponectin and Controls Apoptosis in Yeast Through a Homolog of Human Adiponectin Receptor. Mol Cell 17:171-180, 2005

• 8) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 9) Hada Y et al:Selective purification and characterization of adiponectin multimer species from human plasma. Biochem Biophys Res Commun 356(2):487-493, 2007
  pubmed

• 10) Spranger J et al:Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226-228, 2003
  pubmed

• 11) Ebinuma H et al:A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chim Acta 372:47-53, 2006
  pubmed

• 12) Hara K et al:Measurement of the high-molecular- weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357-1362, 2006
  pubmed

P.370 掲載の参考文献

• 1) Matsuzawa Y et al:Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 2) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 3) Keaney JF et al:Obesity and systemic oxidative stress:clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23:434-439, 2003
  pubmed

• 4) Houstis N et al:Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440:944-948, 2006
  pubmed

• 5) Furukawa S et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
  pubmed

• 6) Griendling KK et al:NAD (P)H oxidase:role in cardiovascular biology and disease. Circ Res 86:494-501, 2000
  pubmed

• 7) Fortuno A et al:Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 55:209-215, 2006
  pubmed

• 8) Inoguchi T et al:High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes 49:1939-1945, 2000
  pubmed

• 9) Sutherland WH et al:Vitamin E supplementation and plasma 8-isoprostane and adiponectin in overweight subjects. Obesity 15:386-391, 2007
  pubmed

• 10) Kugi M et al:Antioxidative effects of fluvastatin on superoxide anion activated by angiotensin II in human aortic smooth muscle cells. Cardiovasc Drugs Ther 16:203-207, 2002
  pubmed

• 11) Wassmann S et al:Cellular antioxidant effects of atorvastatin in vivo and in vitro. Arterioscler Thromb Vasc Biol 22:300-305, 2002
  pubmed

• 12) Nakamura T et al:Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 193:449-451, 2007
  pubmed

• 13) Sakamoto K et al:The effect of 6 months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia:a pilot study. Clin Ther 28:1012-1021, 2006
  pubmed

• 14) Kurata A et al:Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tisue and ameliorates adipocytokine dysregulation. Kidney Int 70:1717-1724, 2006

• 15) Furuhashi M et al:Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:7681, 2003

• 16) Julius S et al:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomised trial. Lancet 363:2022-2031, 2004

• 17) Weisberg SP et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003
  pubmed

• 18) Xu H et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J Clin Invest 112:1821-1830, 2003

• 19) Wang B et al:Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture:integratedresponse to TNF-α. Am J Physiol Endocrinol Metab 288:E731-E740, 2005

• 20) Kanda H et al:MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116:1494-1505, 2006

• 21) Weisberg SP et al:CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116:115-124, 2006
  pubmed

• 22) Inouye KE et al:Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56:2242-2250, 2007

• 23) Komai N et al:Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction inpatients with rheumatoid arthritis. Mod Rheumatol 17:385-390, 2007

• 24) Hirosumi J et al:A central role for JNK in obesity and insulin resistance. Nature 420:333-336, 2002
  pubmed

• 25) Hotamisligil GS:Inflammation and metabolicdisorders. Nature 444:860-867, 2006
  pubmed

P.375 掲載の参考文献

• 1) Kadowaki T, Yamauchi T:Adiponectin and adiponectin receptors. Endocr Rev 26:439-451, 2005
  pubmed

• 2) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 3) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

• 4) International-Diabetes-Federation:The IDF consensus worldwide definition of the metabolic syndrome. Article online. Available from www.idf.org/webdata/docs/Metac_syndrome_def.pdf. Accessed 15 June 2005, 2005

• 5) Yang WS et al:Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819, 2001
  pubmed

• 6) Kopp HP et al:Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond) 29:766-771, 2005
  pubmed

• 7) Hulver MW et al:Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 283:E861-865, 2002

• 8) Sato F et al:Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. J Clin Endocrinol Metab 92:3326-3329, 2007
  pubmed

• 9) Petersen KF et al:Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54:603-608, 2005
  pubmed

• 10) Tamura Y et al:Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191-3196, 2005
  pubmed

• 11) Mousavinasab F et al:Lack of increase of serum adiponectin concentrations with a moderate weight loss during six months on a high-caloric diet in military service among a young male Finnish population. Endocrine 26:65-69, 2005

• 12) Giannopoulou I et al:Effects of diet and/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes. Metabolism 54:866-875, 2005

• 13) Ryan AS et al:Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord 27:1066-1071, 2003

• 14) Esposito K et al:Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women:a randomized trial. JAMA 289:1799-1804, 2003
  pubmed

• 15) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 16) Bluher M et al:Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle:associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 91:2310-2316, 2006
  pubmed

• 17) Polak J et al:Effect of aerobic training on plasma levels and subcutaneous abdominal adipose tissue gene expression of adiponectin, leptin, interleukin 6, and tumor necrosis factor alpha in obese women. Metabolism 55:1375-1381, 2006
  pubmed

• 18) O'Leary VB et al:Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J Appl Physiol 100:1584-1589, 2006

• 19) Krikctos AD et al: Exercise increases adiponectin levels and insulin sensitivity in humans. Diabetes Care 27:629-630, 2004

• 20) Ring-Dimitriou S et al:The effect of physical activity and physical fitness on plasma adiponectin in adults with predisposition to metabolic syndrome. Eur J Appl Physiol 98:472-481, 2006
  pubmed

• 21) Marcell TJ et al:Exercise training is not associated with improved levels of C-reactive protein or adiponectin. Metabolism 54:533-541, 2005

• 22) Kondo T et al:Effect of exercise on circulating adipokine levels in obese young women. EndocrJ 53:189-195, 2006
  pubmed

• 23) Nassis GP et al:Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metabolism 54:1472-1479, 2005
  pubmed

• 24) Pajvani UB et al:Complex distribution, notabsolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement ininsulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

• 25) O'Leary VB et al:Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab 293:E421-427, 2007

• 26) Pischon T et al:Plasma adiponectin levels andrisk of myocardial infarction in men. JAMA 291:1730-1737, 2004

6. アディポネクチンに関する主要な疫学・臨床研究

P.384 掲載の参考文献

• 1) Pischon T et al:Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
  pubmed

• 2) Grobbee DE et al:Coffee, caffeine, and cardiovascular disease in men. N Engl J Med 323:1026-1032, 1990

• 3) Rimm EB et al:Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 338:464-468, 1991
  pubmed

• 4) Rimm EB et al:Reproducibility and validity of an expanded seif-administered semi quantitative food frequency questionnaire among male health professionals. Am J Epidemiol 135:1114-1126, 1992

• 5) Giovannucci E et al:The assessment of alcohol consumption by a simple self-administered questionnaire. Am J Epidemiol 133:810-817, 1991
  pubmed

• 6) Chasan-Taber S et al:Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 7:81-86, 1996
  pubmed

• 7) Pischon T et al:Adiponectin:stability in plasma over 36 hours and within person variation over 1 year. Clin Chem 49:650-652, 2003
  pubmed

• 8) Schulze MB et al:Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54:534-539, 2005
  pubmed

• 9) Pai JK et al:Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351:2599-2610, 2004
  pubmed

• 10) Chu N-F et al:Plasma insulin, leptin, soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157:495-503, 2001
  pubmed

• 11) Schlegel A:Adiponectin and risk of coronary heart disease. JAMA 292:40, 2004.
  pubmed

P.390 掲載の参考文献

• 1) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most Abundant Gene Transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 2) Matsuzawa Y et al:Adiponectin and metabolic syndrome. Aeterioscler Thromb Vasc Biol 24:29-33, 2004
  pubmed

• 3) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 4) Ryo M et al:Adiponectin as a biomarker of the metabolic syndrome. Circ J 68:975-981, 2004
  pubmed

• 5) Hotta K et al:Plasma concentration of a novel adipose-specific ptorein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 6) Daimon M et al:Funagata study:Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population:the Funagata study. Diabetes Care 26:2015-2020, 2003
  pubmed

• 7) Choi KM et al:Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol 61 (1):75-80, 2004
  pubmed

• 8) Lindsay RS et al:Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57-58, 2002
  pubmed

• 9) Ouchi N et al:Novel modulator for endotherialadhesion molecules:adipocyte-derived plasmaprotein adiponectin. Circulation 100:2473-2476, 1999

• 10) Kumada M et al:Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003
  pubmed

• 11) Pischon T et al:Plasma adiponectin levels andrisk of myocardial infarction in men. JAMA 291:1730-1737, 2004

• 12) Zoccali C et al:Adiponectin, metabolic risk factors, and cardiovascular events among patientswith end-stage renal disease. J Am Soc Nephrol13:134-141, 2002

• 13) George J et al:Circulating adiponectin concentrations in patients with congestive heart failure. Heart 92:1420-1424, 2006
  pubmed

• 14) Tsutamoto T et al:Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 28:1723-1730, 2007

P.398 掲載の参考文献

• 1) 財団法人国際協力医学研究振興財団 (JF-PIMRC) http://www.pimrc.or.jp/

• 2) Yazaki Y, Kadowaki T:Combating diabetes and obesity in Japan. Nat Med 12:73-74, 2006
  pubmed

• 3) J-DOIT3 http://www.jdoit3.jp/

• 4) Gaede P et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
  pubmed

• 5) Gaede P et al:Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591, 2008
  pubmed

• 6) 日本糖尿病学会編:科学的根拠にもとづく糖尿病 診療ガイドライン, 第2版, 南江堂, 東京, 2007

• 7) 日本糖尿病学会編:糖尿病治療ガイド2008-2009, 文光堂, 東京, 2008

• 8) Dormandy JA et al:PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366(9493):1279-1289, 2005
  pubmed

• 9) Kawamori R et al:on behalf of the PRACTICAL Study Group:Hepatic safety profile and glycemic control of pioglitazone in more than 20, 000 patients with type 2 diabetes mellitus:Postmarketing surveillance study in Japan. Diabetes Res Clin Pract 76:229-235, 2007

• 10) Ninomiya T et al:Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population:the Hisayama study. Stroke 38(7):2063-2069, 2007

• 11) Kubota N et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathway. J Biol Chem 281:8748-8755, 2006

• 12) Nakamura H et al:Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study):a prospective randomized controlled trial. Lancet 368(9542):1155-1163, 2006
  pubmed

• 13) Colhoun HM et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet 364(9435):685-696, 2004
  pubmed

7. アディポネクチン研究の実際―実験法

P.405 掲載の参考文献

• 1) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120(4):803-812, 1996
  pubmed

• 2) Nakano Y et al:A novel enzyme-linked immunosorbent assay specific for high-molecular weight adiponectin. J Lipid Res 47:1572-1582, 2006
  pubmed

• 3) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin:Implications for metabolic regulation and bioactivity. J Biol Chem 278(11):9073-9085, 2003
  pubmed

P.416 掲載の参考文献

• 1) http://www.ncbi.nlm.nih.gov/projects/sviewer/?id=NC_000082.5&v=23146609-23158041

• 2) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277:25863-25866, 2002
  pubmed

• 3) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737, 2002
  pubmed

• 4) Ma K et al:Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem 277:34658-34661, 2002
  pubmed

• 5) Nawrocki AR et al:Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281:2654-2660, 2006
  pubmed

• 6) Kubota N et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and-independent pathways. J Biol Chem 281:8748-8755, 2006
  pubmed

• 7) Kadowaki T, Yamauchi T:Adiponectin and adiponectin receptors. Endocr Rev 26:439-451, 2005
  pubmed

• 8) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 9) Combs TP et al:Atransgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367-383, 2004

• 10) Kim JY et al:Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117:2621-2637, 2007
  pubmed

• 11) Otabe S et al:Overexpression of human adiponectin in transgenic mice results in suppression of fat accumulation and prevention of premature death by high-calorie diet. Am J Physiol Endocrinol Metab 293:E210-218, 2007
  pubmed

• 12) Bauche IB et al:Overexpression of adiponectin targeted to adipose tissue in transgenic mice:Impaired adipocyte differentiation. Endocrinology 148:1539-1549, 2007
  pubmed

• 13) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 14) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 15) http://www.ncbi.nlm.nih.gov/projects/sviewer/?id=NC_000067.5&v=136311201..136329761

• 16) http://www.ncbi.nlm.nih.gov/projects/sviewer/?id=NC_000072.5&=119303168-119367501

• 17) Yamauchi T et al:Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339, 2007
  pubmed

• 18) Bjursell M et al:Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56:583-593, 2007
  pubmed

• 19) Liu Y et al:Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology 148:683-692, 2007
  pubmed

• 20) Kadowaki T et al:Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784-1792, 2006
  pubmed